A. Representative Publications in Recent 5 Years as a Corresponding Author:

1. Youngquist, B., Saliba, J., Kim, Y., Cutro, T., Lyon, C., JOlivo, J., Ha, N., Colman, R., Vergara,

C.,Garfein, R., Catanzaro, D., Perez-Then, E., Graviss, E., Mitchell, C., Rodwell, T., Ning, B., Hu, T.* Rapid tuberculosis diagnosis from respiratory or blood samples by a low cost, portable lab-intube assay. Science Translational Medicine. 2025, 17, eadp6411.(Cover Story).

2. Ning, B., Chandra, S., Pan, Y., Ha, N., Singh, S., Varela, A., Li, L., Wu, Q., Kay, A., Maphalala, G.P.,

Adu-Gyamfi, C., Longlax, S., Mandalakas, A. M., Lyon, C., Graviss, E. A., DiNardo, A. R., Hu, T.* Self-Powered Rapid Antigen-Specific T cell Response Assay for Mycobacterium Tuberculosis Infections. Nature Biomedical Engineering. 2025, doi.org/10.1038/s41551-025-01441-5.

3. Saliba, J. G., Zheng, W., Shu, Q., Li, L., Qu, J., Xie, Y., Ying, B., Huang, H., Lyon, C. J., Hu, T.*Enhanced diagnosis of multi-drug-resistant microbes using group association modeling and machine learning. Nature Communications. 2025, 16:2933.

4. Huang, Z., Song, Z., Zeng, J., Liu, X., Fang, M., Chen, Y., Li, D., Huang, H., Fu, L., Xu, P., Ning, B., Lyon, C., Fan, X., Lu, S., Hu, T.* Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage. Nature Communications. 2025, 16:8257.

5. Wu, J., Dou, Q., Mao, M., Wan, X., Hu, T.*, Zhang, Y.* Single extracellular vesicle imagin g via rolling circle amplification–expansion microscopy. Nature Communications. 2025, 16:7498.

6. Zheng, W., LaCourse, S., Song, B., Singh, D. K., Khanna, M., Olivo, J., Stern, J., Escudero, J., Vergara,

C., Zhang, F., Li, S., Wang, S., Cranmer, L.M., Huang, Z., Bojanowsk, C.M., Bao, D., Njuguna, I., Xiao,Y., Wamalwa, D. C., Nguyen, D. T., Yang, L., Maleche-Obimbo, E., Nguyen, N., Zhang, L., Phan, H.,Fan, J., Ning, B., Li, C., Lyon, C. J., Graviss, E. A., John-Stewart, G., Mitchell, C. D., Ramsay, A. J., Kaushal,D., Liang, R., Pérez-Then, E., Hu, T.* Diagnosis of paediatric tuberculosis by optically detecting two virulence factors on extracellular vesicles in blood samples. Nature Biomedical Engineering. 2022. 6, 979-991.

7. Huang, Z., LaCourse, S., Kay A., Stern, J., Escudero, J., Youngquist, B., Zheng, W., Vambe, D., Dlamini, M., Mtetwa, G., Cranmer, L., Njuguna, I., Wamalwa, D., Maleche-Obimbo, E., Catanzaro, D., Lyon, C., John-Stewart, G., DiNardo, A., Mandalakas, A., Ning, B., Hu, T.* CRISPR Detection of Circulating Cell-free M. tuberculosis DNA in Adults and Children, Including Children with HIV. The Lancet Microbe. 2022, 3(7): E482-492.

8. Zheng, W., Shu, Q., Mao L., Lyon, C., Li, C., Hu, T.* Nanopore-based disease diagnosis using pathogen-derived tryptic peptides from serum. Nano Today. 2022, 45:101515.

9. Ning, B., Youngquist, B. M., Li, D. D., Lyon, C. J., Zelazny, A., Maness4, N. J., Tian, D., Hu, T.* Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting Mutations. Cell Reports Method. 2022. 2(2):100173.

10. Ning, B., Chandra, S., Rosen, J., Evan, M., Melvin, A., Lane, P., Ivy, T., Brittany, S., Escarra, M., Stacy, D., Zwezdary, K., Lyon, C., Norton, E., Hu, T.* Evaluation of pathogen specific T-cell activation with a point-of-care on-chip IGRA. ACSNano. 2022, 17(2):1206-1216.

11. Ning, B., Huang, Z., Youngquist, B. M, Scott, J. W., Niu, A., Bojanowski, C., M., Zwezdaryk, K. J.,Saba, N., S., Fan, J., Yin, X., Cao, J., Lyon, C. J., Li, C., Roy, C. J., Hu, T.* Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. Nature Nanotechnology. 2021. 16, 1039-1044.

12. Ning, B., Yu, T., Zhang, S., Huang, Z., Tian, D., Lin, Z., Niu, A., Golden, N., Hensley, K., Threeton, B., Lyon, C. J., Yin, X., Saba, N., Rappaport, J., Wei, Q., Hu, T.* A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. Science Advances. 2021. 7(2): eabe3703.

13. Huang, Z., Ning, B., Yang, H., Youngquist, B., Niu, A., Lyon, C., Beddingfield, B., Fears, A., Monk, C., Murrell, A., Bilton, S., Linhuber, J., Norton, E., Dietrich, M., Lai, W., Scott, J., Yin, X., Rappaport,

J., Robinson, J., Saba, N., Roy, C., Zwezdaryk, K., Zhao, Z., Hu, T.* Sensitive tracking ofviral RNA in plasma through all stages of SARS-CoV-2 infection. J. ClinicalInvestigation. 2021, 131(7):e146031.

14. Liu, Y., Fan, J., Xu, T., Ahmadinejad, N., Hess, K., Lin, S., Zhang, J., Liu, X., Liu, X., Ning, B., Liao, Z., Hu, T.* Extracellular Vesicle Tetraspanin-8 Expression Predicts Distant Metastasis in NonSmall Cell Lung Cancer after Concurrent Chemoradiation. Science Advances. 2020, 6:11, eaaz6162.

15. Rodrigues, M., Richards, N., Ning, B., Lyon, C., Hu, T.* Rapid lipid-based normalization of membrane protein expression on extracellular vesicles in complex biological samples. Nano Letters. 2019, 19, 11, 7623-7631 (Cover Story).

16. Liu, C., Zhao, Z., Fan, J., Lyon, C. J., Wu, H., Nedelokv, D., Zelazny, A.M., Olivier, K.N., Cazares,

L.H., Holland, S.H., Graviss, E. A., Hu, T.* Quantification of Circulating M. tuberculosis Antigens for Rapid Diagnosis and Real-time Treatment Monitoring. Proc. Natl. Acad. Sci. USA. 2017, 114(15):3969-3974. (Highlighted by New EnglandJournal ofMedicine)

17. Liang K., Liu, F., Fan, J., Sun, D., Bernard, D. W., Li, Y., Yokoi, K., Katz, M. H., Koay, E. J., Zhao, Z., Hu, T.* Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nature Biomedical Engineering. 2017,

1:0021. (Highlighted by Nature Review Gastroenterology & Hepatology)

B. Other Publications in 15 years

1. Youngquist, B., Pungan, D., Dai, G., Abdelgallel, Y., Lyon, C., Ning, B., Husain, S., Kolls, J.,Hu, T. CRISPR-mediated detection of Pneumocystis transcripts in bronchoalveolar, oropharyn geal, and serum specimens for Pneumocystis pneumonia diagnosis. J. Clinical Investigation. 20 25,135(8):e177241.

2. Li, L., Mao, L., van der Zalm, M. M., Olivo, J., Liu, S., Vergara, C., Palmer, M., Shu, Q., Demers, A., Lyon, C. J., Goussard, P., Schaaf, S., Hesseling, A. C., Nachman, S., Pérez-Then, E., Mitchell, C. D., Ghimenton, E., Hu, T. Blood-based diagnosis of pediatric tuberculosis: a prospective cohort study in South Africa and Dominican Republic. Journal of Infection. 2025, 90(2):106404.

3. Li, Z., He, B., Li, Y-W., Liu, B., Zhang, G., Liu, S.*, Hu, T. *, Li, Y. * Synergizing NanosensorEnhanced Wearable Devices with Machine Learning for Precision Health Management Benefitting Older Adult Populations. ACS Nano. 2025. In press.

4. Tran, H., Zheng, W.*, Issadore, D., Im, H., Cho, Y.-K., Zhang, Y., Liu, D., Liu, Y., Liu, F., Li, B., Wong, D., Sun, J., Qian, K., He, M., Wan, M., Zeng, Y., Cheng, K., Huang, T., Chiu, D., Lee, L., Zheng, L., Godwin, A., Kalluri, R., Soper, S. A., Hu, T.* Extracellular vesicles for clinical diagnostics:

from bulk measurements to single-vesicle analysis. ACS Nano. 2025. In press.

5. Su, Y., He, W., Zheng, L., Fan, X., Hu, T. Towards Clarity in Single Extracellular Vesicle Research:

Defining the Field and Correcting Missteps. ACS Nano. 2025, 6;19(17):16193-16203.

6. Lai, L., Su, Y., Hu, C., Peng, Z., Xue, W. Dong, L., Hu, T. Integrating aggregate materials and machine learning algorithms: advancing detection of pathogen-derived extracellular vesicles.

Aggregate. 2025, Accepted.

7. Liao, H., Zhang, F., Chen, F., Li, Y., Sun, Y., Sloboda, D. D., Zheng, Q., Ying, B., Hu, T. Application of Artificial Intelligence in Laboratory Hematology: Advances, Challenges, and Prospects. Acta Pharmaceutica Sinica B. 2025, Accepted.

8. Zhu, D., Ma, X., Wang, J., Chen, T., Yang, J., Liu, Y., Lin, Z., Wu, M.*, Hu, T.*, Zhang, Y.* A Sequential Release Micro-nano System for Colitis Therapy via Gut Microbiota and Immune Regulation. Angewandte Chemie. 2025, Accepted.

9. Bao, D., Maity, S., Zhan, L., Seo, S., Shu, Q., Ning, B., Zelazny, A., Hu, T., Fan, J. Precise Mycobacterial Species and Subspecies Identification Using the PEP-TORCH Peptidome Algorithm.

EMBO Molecular Medicine. 2025, 17: 841 – 861.

10. Liu, Y., Zhang, Y., Li, H., Hu, T. Recent advances in the bench-to-bedside translation of cancer nanomedicines. Acta Pharmaceutica Sinica B. 2024, 15(1):97-122.

11. Li, L., Mao, L., van der Zalm, M. M., Olivo, J., Liu, S., Vergara, C., Palmer, M., Shu, Q., Demers, A.,

Lyon, C. J., Goussard, P., Schaaf, S., Hesseling, A. C., Nachman, S., Pérez-Then, E., Mitchell, C. D., Ghimenton, E., Hu, T. Blood-based diagnosis of pediatric tuberculosis: a prospective cohort study in South Africa and Dominican Republic. Journal of Infection. 2025, 90(2):106404.

12. Qian, X., Xu, Q., Lyon, C., Hu, T. CRISPR for companion diagnostics in low-resource settings. Lab-on-aChip. 2024, 24,4717-4740.

13. Treekitkarnmongkol W., Dai J., Liu S., Sankaran D., Nguyen T., Balasenthil S., Hurd M.W., Chen M.,

Katayama H., Roy-Chowdhuri S., Calin G.A., Brand R.E., Lampe P.D., Hu T., Maitra A., Koay E.J., Killary A.M., Sen S. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal

Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Gastro Hep Adv. 2024.

3(8):1098-1115.

14. Chen, X., Gao, Y., Qi, Y., Li, J., Hu, T., Chen, Z., Zhu J. Label-Free Raman Probing the Intrinsic Electric Field for High-Efficiency Screening of Electricity-Producing Bacteria at Single-Cell Level.

Angewandte Chemie. 2024, e202416011.

15. Sabino-Santos G., Leggio C.E., Litwin S.M., Waheed N., Bai S., Ulusan S., Karunathilake A., Elliott D.H., Smira A.R., Chandra S., Li L., Ning B., Hu T., Schieffelin J.S., Gunn B.M., Robinson J.E., Fuloria J., Norton E.B.. Post-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodies. Immun Inflamm Dis. 2024.

12(12):e70039.

16. Wang J, Liang S, Zhu D, Ma X, Peng Q, Wang G, Wang Y, Chen T, Wu M, Hu T, Zhang Y. Valence-

Change MnO₂-Coated Arsenene Nanosheets as a Pin1 Inhibitor for Hepatocellular Carcinoma Treatment. J. Am. Chem. Soc. 2024, 146(31):21568-21582.

17. Bao, D., Maity, S., Zelanzny, A., Lyon, C., Hu, T., Fan, J. Improving Targeted Mass Spectrometry Data Analysis with Nested Active Machine Learning. Advanced Intelligent Systems. 2024, 6, 2300773.

18. Li, L., Henkle, E., Youngquist, B., Seo, S., Hamed, K., Melnick, D., Lyon, C., Jiang, L., Zelazny, A., Hu, T., Winthrop, K., Ning, B. Serum cell-free DNA-based detection of Mycobacterium avium complex infection. Am. J. Respir. Crit. Care Med. 2024, 209(10):1246-1254.

19. Das, S., Lyon, C., Hu, T. A Panorama of Extracellular Vesicle Applications: From Biomarker Detection to Therapeutics. ACSNano. 2024, 18(14):9784-9797.

20. Liao, H., Lyon, C., Ying, B., Hu, T. Climate change, its impact on emerging microbial infectious diseases and new technologies to combat the challenge. Emerging Microbes & Infections. 2024, 13(1):2356143.

21. Huang G., Zheng, W., Wan, M., Hu, T. Recent Advances to Address Challenges in Extracellular Vesicles-Based Application for Lung Cancer. Acta Pharmaceutica Sinica B. 2024, 14(9):3855-3875.

22. Huang, Z., Lyon, C., Hu, T. CRISPR-based assays for low-resource settings. Nature Reviews Bioengineering. 2023, 1:230-231.

23. Li, L., Lyon, C. J., LaCourse, S. M., Zheng, W., Stern, J., Escudero, J. N., Murithi, W., Njagi, L., John-Stewart, G., Hawn, T., Nduba, V., Abdelgaliel, W., Tombler, T., Horne. D., Jiang, L., Hu, T. Sensitive detection of HIV-1 and Mycobacterium tuberculosis peptides in blood for rapid diagnosis of co-infected individuals by immuno-affinity liquid chromatography tandem mass spectrometry.

Clinical Chemistry. 2023, 69(12):1409-1419.

24. Huang, Z., Lyon, C., Wang, J., Lu, S., Hu, T. CRISPR assays for disease diagnosis: progress to and barriers remaining for clinical applications. Advanced Science. 2023, e2301697.

25. Huang, Z., Zhang, G., Lyon, C., Hu, T., Lu, S. Outlook for CRISPR-based tuberculosis assays now in their infancy. Frontier in Immunology. 2023, 14:1172035.

26. Li, L., Zhang, L., Montgomery, K., Lyon, C., Hu, T. Advanced Technologies for Molecular Diagnosis of Cancer: State of Pre-Clinical Tumor-Derived Exosome Liquid Biopsies. Materials Today Bio. 2023, 100538.

27. Li, L., Wu, J., Lyon, C., Jiang, L., Hu, T. Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications. BME Frontiers. 2023. 4:0019.

28. Li, C.Z. and Hu, T. (2022) Nanotechnology Powered CRISPR-Cas Systems for Point of Care Diagnosis and Therapeutic. Research. 2023. 2022:9810237.

29. Monk, C., Youngquist, B., Brady, A., Shaffer, J., Hu, T., Ning, B., Zwezdaryk, K. Development of a CRISPR-Cas12a rapid diagnostic for human cytomegalovirus. Antiviral Research. 2023. 215:105624.

30. Toraih, E.A., Fawzy, M.S., Ning, B., Zerfaoui, M., Errami, Y., Ruiz, E.M., Hussein, M.H., Haidari,

M.,Bratton, M., Tortelote, G.G., Hilliard, S., Nilubol, N., Russell, J.O., Shama, M.A., El-Dahr, S.S., Moroz, K., Hu, T., and Kandil E. A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. Cancers. 2023. 14(17):4128.

31. Maity, S., Mayer, M., Shu, Q., Bao, D., Blair, R., He, Y., Lyon, C., Hu, T., Fischer, T., Fan, J.

Cerebrospinal fluid protein markers indicate neuro-damage in SARS-CoV-2-infected non-human primates. Molecular and Cellular Proteomics. 2023, 22(4):100523.

32. Zheng, W., Shu, Q., Mao L., Lyon, C., Li, C., Hu, T.* Nanopore-based disease diagnosis using pathogen-derived tryptic peptides from serum. Nano Today. 2022, 45:101515.

33. Ning, B., Youngquist, B. M., Li, D. D., Lyon, C. J., Zelazny, A., Maness4, N. J., Tian, D., Hu, T.* Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting Mutations. Cell Reports Method. 2022. 2(2):100173.

34. Ning, B., Chandra, S., Rosen, J., Evan, M., Melvin, A., Lane, P., Ivy, T., Brittany, S., Escarra, M., Stacy, D., Zwezdary, K., Lyon, C., Norton, E., Hu, T.* Evaluation of pathogen specific T-cell activation with a point-of-care on-chip IGRA. ACS Nano. 2022, 17(2):1206-1216.

35. Wu, J., Lin, Z., Zou, Z., Wu, M., Hu, T.*, Zhang, Y.* Identifying the Phenotypes of Tumor-Derived Extracellular Vesicles using Size-coded Affinity Microbeads. Journal of the American Chemical Society. 2022, 144(51):23483-91.

36. Wang, S., Zheng, W., Zhang, L., Yang, L., Wang, T., Saliba, J., Chandra, S., Chandra, S., Li, C., Lyon, C., Hu, T. Monocrystalline labeling enables stable plasmonic enhancement for isolation-free extracellular vesicle analysis. Small. 2022. 2204298.

37. Yang, L., Liang T., Pierson, L., Wang, H., Fletcher, J., Wang, S., Bao, D., Zhang, L., Huang, Z., Zheng, W., Zhang, X., Park, H., Li, Y., Robinson, J., Feehan, A., Lyon, C., Cao, J., Morici, L., Li, C., Roy, C., Yu, X., Hu, T. SARS-CoV-2 epitopes following infection and vaccination overlap known neutralizing antibody sites. Research. 2022. 9769803.

38. Wei, X., Wang, X., Zhang1, Z., Luo, Y., Wang, Z., Xiong, W., Jain, P., Monnier, J., Wang, H., Hu, T.,

Tang, C., Albrecht, H., Liu, C. A Click Chemistry Amplified Nanopore (CAN) Assay for Ultrasensitive Quantification of HIV p24 Antigen in Clinical Samples. Nature Communications. 2022.

6852.

39. Chandra, S., Hu, T. From Prevention to Therapy- A Roadmap of Nanotechnologies to Stay Ahead of Future Pandemics. ACS Nano. 2022, 16, 7, 9985–9993.

40. Liu, S., Wu, X., Sutapa, C., Lyon, C., Ning, B., jiang, L., Fan, J., Hu, T. Extracellular vesicles: emerging tools as therapeutic agent carriers. Acta Pharmaceutica Sinica B. 2022. 12(10):3822-3842.

41. Huang, Z., Zhang, L., Lyon, C. J., Ning, B., Youngquist, B. M., Niu, A., Beddingfield, B. J., Maness, N. J., Saba, N. S., Li, C., Roy, C. J., Hu, T. CRISPR-based Assay Reveals SARS-CoV-2 RNA Dynamic Changes and Redistribution Patterns in Non-Human Primate Models. Emerging Microbe & Infections. 2022. 11(1):629-638.

42. Rutkai, I., Mayer. M., Hellmers, L., Ning, B., Huang, Z., Monjure, C., Coyne, C., Silvestri, R., Golden,

N., Hensley, K., Chandler, K., Lehmicke, G., Bix, G., Maness, N., Russell-Lodrigue, K., Hu, T., Roy, C., Blair, R., Bohm, R., Doyle-Meyers, L., Rappaport, J., Fisher, T. Neuropathology and Virus in Brain of SARS-CoV-2 Infected Non-Human Primates. Nature Communications. 2022. 13:1745.

43. Alwarappan, S., Nesakumar, N., Sun, D., Hu, T.*, Li, C.* 2D metal carbides and nitrides (MXenes) for Sensors and Biosensors. Biosensors and Bioelectronics. 2022. 205:113943.

44. Shu, Q., Rajagopal, M., Fan, J., Zhan L., Kong X, He Y., Rotcheewaphan, S., Lyon, C. J., Sha, W., Adrian M. Zelazny, A. M., Hu, T. Peptidomic Analysis of Mycobacterial Secreted Proteins Enables Species Identification. View. 2022, 3:20210019.

45. Shu, Q., Liu, S., Alonzi, T., LaCourse, S. M., Singh, D., Bao, D., Wamalwa, D., Jiang, L., Lyon, C. J., John-Stewart, G., Kaushal, D., Goletti, D., Hu, T. Assay Design for Unambiguous Identification and Quantification of Circulating Pathogen-derived Peptide Biomarkers. Theranostics. 2022. 12(6):29482962.

46. Toraih, E.A., Fawzy, M.S., Ning, B., Zerfaoui, M., Errami, Y., Ruiz, E.M., Hussein, M.H., Haidari, M., Bratton, M., Tortelote, G.G., Hilliard, S., Nilubol, N., Russell, J.O., Shama, M.A., El-Dahr, S.S., Moroz, K., Hu, T., Kandil, E. A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. Cancers. 2022, 14, 4128.

47. Oguntoye, I., Simone, B., Padmanabha, S., Hartfield, G., Amrollahi, P., Hu, T., Ollanik, A., Escarra, M. Silicon Nanodisk Huygens Metasurfaces for Portable and Low-Cost Refractive Index and Biomarker Sensing. ACS Applied Nano Materials. 2022. 5(3): 3983-3991.

48. Hu, Q., Zhang, S., Yang, Y., Yao, J., Tang, W., Lyon, C., Hu, T., Wan, M. Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Military Medical Research. 2022, 9:6`.

49. Sun, D., Zhao, Z., Spiegel, S., Liu, Y., Fan, J., Amrollahi, P., Lyon, C. J., Wan, M., Hu, T. Dye-free spectrophotometric measurement of nucleic acid-to-protein ratio for cell selective extracellular vesicle discrimination. Biosensors and Bioelectronics. 2021. 179: 113058.

50. Shu, Q., Kenny, T., Fan, J., Lyon, C., Cazares, L., Hu. T. Species-specific Quantification of Circulating Ebolavirus Burden using VP40-derived Peptide Variants. PLOS Pathogens. 2021. 17(11): e1010039.

51. Nakao, Y., Amrollahi, P., Parthasarathy, G., Mauer, A. S., Sehrawat, T. S., Vanderboom, P., Nair, S., Nakao, K., Allen, A. M., Hu, T.*, Malhi, H.* Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine: BME. 2021. 36:102430.

52. Rao, J., Hu, T., Teck, L., Han, D. Mechanics of cancer and cancer cells – a 4^th dimension? Frontier in Cell and Development Biology. 2021, 9:775012.

53. Liu, W., Zhu, X., Mozneb, M., Nagahara, L., Hu, T., Li, C. Lighting up ATP in cells and tissues using a simple aptamer-based fluorescent probe. Microchimica Acta. 2021, 188(10):352.

54. Amrollahi, P., Zheng, W., Monk, C., Li, C., Hu, T. Nanoplasmonic sensor approaches for sensitive detection of disease-associated exosomes. ACS Applied Bio Materials. 2021, 4 (9): 6589–6603.

55. He, Y., Lyon, C. J., Nguyen D. T., Liu, C., Sha, W. Graviss, E., Hu, T.* Serum-based diagnosis of pediatric tuberculosis by assay of Mycobacterium tuberculosis factors: a retrospective cohort study. J. Clin. Micro. 2021. 59(2): e01756-20.

56. Chen, X., Hu, T.* Strategies for advanced personalized tuberculosis diagnosis. Precision Clinical Medicine. 2021. 4(1): 35-44.

57. Hu, T.*, Walfrom, J. E., Srivastava, S. * Extracellular Vesicles in Cancer Detection: Hopes and Hypes.

Cell: Trends in Cancer. 2021, 7(2): 122-133.

58. He, X., Howard, B. A., Liu, Y., Neumann, A. K., Li, L., Menon, N., Roach, T., Kale, S. D., Samuels, D. C., Li, H., Kite, T., Kita, H., Hu, T., Luo, M., Jones, C. N., Okaa, U., Squillace, D. L., Klein, B. S., Lawrence, C. B. LYSMD3: a mammalian pattern recognition receptor for chitin. Cell Report. 2021.

36: 109392.

59. Hu, Q., Lyon, C. J., Fletcher, J. K., Tang, W., Wan, M., Hu, T.* Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses. Acta Pharmaceutica Sinica B.

2021. 11(6): 1492-1512.

60. Niu, A., Ning, B., Socola, F., Safah, J. H., Reynolds, T., Ibrahim, M., Safa, F., Luk A. T., Mushatt, D. M., Hu, T., Saba N. S. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. Leukemia Research. 2021, 160:106582.

61. Tian, D., Lin, Z., Kriner, E. M., Esneault, D. J., Tran, J., DeVoto, J. C., Okami, N., Greenberg, R., Yanofsky, S., Ratnayaka, S., Tran, N., Livaccari, M., Lampp, M., Wang, N., Tim, S., Norton, P., Scott, J., Hu, T., Garry, R., Hamm, L., Delafontaine, P., Yin, X. M. Ct Values do not Predict SARS-CoV-2 Transmissibility in College Students. J Mol Diagn. 2021. 21:00163-X.

62. Jain, S. Nehra, M., Kumar, R., Dilbaghi, N., Hu, T., Kumar, S., Kaushik, A., Li, C. Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. Biosensors and Bioelectronics. 2021. 179:113074.

63. Mao, L., Lacourse, S., Kim, S., Ning, B., Bao, D., Fan, J., Sun, Z., Nackman, S., Mitchelle, C., Hu, T.* Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years. BMC Medicine. 2021, 19:113.

64. Niu, A., Ning, B., Socola, F., Safah, H., Reynolds, T., Ibrahim, M., Safa, F., Alfonso, T., Luk, A., Mushatt, D., Hu, T., Saba, N. S. COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality. Blood. 2020, 136 (1): 6-7.

65. Hu, T.*, Frieman, M.*, Walfram, J.* Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature Nanotechnology. 2020, 15:247-249.

66. Hu, Q., Fletcher, J. K., Tang, W., Lyon, C. J., Wan, M., Hu, T.* Macrophages and secreted EVmediated interaction loops in inflammatory disease. Acta Pharmaceutica Sinica B. 2020. 11(6): 14931512.

67. Liu, J., Wan, M., Lyon, C., Hu, T.* Nanomedicine therapies modulating macrophage dysfunction: a potential strategy to attenuate cytokine storms in severe infections. Theranostics 2020, 10(21): 95919600.

68. Sun, D., Lyon, C., Hu, T.* Simulation-directed amplifiable nanoparticle enhanced quantitative scattering assay under low magnification darkfield microscope. Journal of Material Chemistry B 2020, 8: 5416-5419.

69. Moss, D.L., Song, K., Wanek, A.G., Shu, Q., Hu, T., Kolls, J.K., Mettu, R.R., Landry, S.J. Destabilization of exotoxin A diminishes serum antibody titer and affinity maturation by reducing peptide-MHCII abundance. J. Immunology 2020, 204 (1 Supplement) 217.17.

70. Beddingfield, B., Iwanaga, N., Zheng, W., Roy, C.J. Hu, T., Kolls, J., Bix, G. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. J Am Coll Cardiol. 2020,

06(15):153387.

71. Pal, P., Ibrahim, M., Niu, A., Zwezdaryk, K.J., Tatje, E., Robinson, W.R., IV, Ko, L., Satyavarapu, I., Jones, W.E., Nachabe, A., Luk, A., Mushatt, D.M., Halvorson, K., Denson, J.L., Smith, C.C., III,

Simeone, F., Davis, G., Gill, S.K., McDougal, A., Vigh, A.S., Peterson, T.G., Ning, B., Hu, T., Socola,

F., Robinson, J., Safah, H. and Saba, N.S. Safety and Efficacy of COVID-19 Convalescent Plasma in Severe Pulmonary Disease, A Report of Seventeen Patients. Transfusion Medicine. 2020, 1(3):217220.

72. Niu, A., McDougal, A., Ning, B., Safa, F., Luk, A., Mushatt, D., Fusco, D., Nachabe, A., Zwezdaryk, K., Robinson, J., Socola, F., Safah, H., Hu, T., Saba, N. S. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent. Bone Marrow Transplantation 2020, 55:2354-2356.

73. Huang, Z., Tian, D., Liu, Y., Lin, Z., Lyon, C., J., Lai, W., Fusco, D., Drouin, A., Yin, X., Hu, T.^*,

Ning, B.^* Ultra-sensitive and high-throughput CRISPR-powered COVID-19 diagnosis. Biosensor and Bioelectronics 2020. 164: 112316.

74. Sehrawat, T. S., Arab, J. P., Liu, M., Amrollahi, P., Wan, M., Fan, J., Nakao, Y., Dasgupta, D., Liao, C., Navarro-Corcuera, A., Pose, E., He, L., Mauer, A., Ventura-Cots, M., Bataller, R. A., Sanyal,

A., J., Chalasani, N. P., Heimbach, J. K., Watt, K. D., Gores, G. J., Gines, P., Kamath, P. S., Simonetto,

D. A., Hu, T., Shah, V. H., Malhi, H. Circulating EVs carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis. Hepatology. 2020, 73(2):571-585.

75. Shu, Q., Li, M., Shu, L., An, Z., Wang, J., Lv, H., Yang, M., Cai, T., Hu, T., Fu, Y., Yang, F. Largescale Identification of N-linked Intact Glycopeptides in Human Serum using HILIC Enrichment and Spectral LibrarySearch. Mol Cell Proteomics. 2020, 19(4):672-689.

76. Hu, Q., Su, H., Li, J., Lyon, C., Tang, W., Wan, M., Hu, T.* Clinical Applications of Exosome Membrane Proteins. Precision Clinical Medicine. 2020, 3(1): 54–66.

77. Wan, M., Spiegel, S., Lyon, C., Hu, T.* Tumor-derived exosomes (TEXs): how to avoid the sting in the tail. Medicinal Research Reviews. 2020, 40(1): 385-412 (Cover Story).

78. Liu, Y., Gu, Y., Lyon, C. J., Fan, J., Koay, E., Katz, M., Han, H., Von Hoff, D., Hu, T.* Circulating levels of hydroxylated bradykinin function as an indicator of tissue HIF-1α expression. Science Bulletin. 2020,65(18): 1570-1579.

79. Hu, X., Chen, H., Liao, S., Bai, H., Gupta, S., Zhou, Y., Zhou, J., Jiao, L., Wu, L., Wang, M., Chen, X., Zhou, Y., Lu, X., Hu, T., Zhang, Z., Ying, B. LncRNA and predictive model for improving the diagnosis of clinically diagnosed pulmonary tuberculosis. Journal of Clinical Microbiology, 2020, 58(7): e01973-19.

80. Rodrigues, M., Richards, N., Ning, B., Lyon, C., Hu, T.* Rapid lipid-based normalization of membrane protein expression on extracellular vesicles in complex biological samples. Nano Letters.

2019, 19, 11, 7623-7631 (Cover Story).

81. Amrollahi P., Rodrigues M., Lyon, C. J., Goel, A., Han, H., Hu, T.* Ultra-sensitive automated profiling of EpCAM expression on tumor-derived extracellular vesicles. Frontiers in Genetics, 2019, 10:1273.

82. Zhang, F., Lyon, C. J., Fan, J., Hu, T.* A cathepsin B-dependent cleavage product of serum amyloid A identifies patients with chemotherapy-related cardiotoxicity. ACS Pharmacology and Translational Science. 2019, 2, 5, 333-341 (Cover Story).

83. Wan, M., Wang, Y., Zhan, L., Fan, J., Hu, T.* MALDI-TOF mass spectrometry-based quantification of C-peptide in diabetes patients. European Journal of Mass Spectrometry. 2019, 26(1):55-62.

84. Deng, Z., Zhao, Z., Basilio, J., Ye, Y., Mann, K., Fu, J., Gu, Y., Wu, X., Chiao, P., Hu, T.* Nanotrapenabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection.

Nano Research. 2019, 12(6): 1445-1452.

85. Hu, T.* Nickel affinity: A sensible approach for extracellular vesicles isolation? Lancet:

EBioMedicine. 2019, 44:14-15.

86. Zhao, Z., Ning, B. Lyon, C., Hu, T.* Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application. Lab-on-a-Chip. 2019, 19(7):1114-1140 (Cover Story).

87. Droll, S. H., Hsu, Y. M. S., Drake, S. K., Kim, A., Wang, W., Calvo, K. R., Cao, Z., Hu, T., Zhao,

Z. Differential Processing of High‐Molecular‐Weight Kininogen during Normal Pregnancy. Rapid Communications in Mass Spectrometry. 2019 Aug 14.

88. Wan, M., Sun, D., Lyon, C., Hu, T.* Using Nanoplasmon-enhanced scattering and low-magnification microscope imagery to quantify pathogen-driven exosome in micro amount of plasma. J Vis Exp. 2019, (147), e59177.

89. Liu, C., Lyon, C. J., Deng, Z., Walters, E., Li, Y., Zhang, L., Hesseling, A., Graviss, E. A., Hu, T.* Clinical evaluation of a blood assay to diagnose paucibacillary tuberculosis via bacterial antigens.

Clinical Chemistry 2018, 64(7): 1 (Cover Story).

90. Fan, J., Wei, Q., Koay, E. J., Bernard, P.W., Kai, M., Borsoi, C., Bernard, D.W., Zhang, N., Katz, M.H., Yokoi, K., Zhao, Z., Hu, T.* Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer. Theranotics. 2018, 8(21):5986-5994 (Cover Story).

91. Rodrigues, M., Fan, J., Lyon, C. J., Wan, M., Hu, T.* Role of Extracellular Vesicles in Viral and

Bacterial Infections: Pathogenesis, Diagnostics, and Therapeutics. Theranostics 2018, 8(10): 2709-272

92. Zou, R., Cao, W., Chong, L., Hua, W., Xu, H., Mao, Y., Page, J., Shi, R., Xia Y., Hu, T., Zhang, W., Ouyang, Z. Point-of-Care Tissue Analysis Using Miniature Mass Spectrometer. Analytical Chemistry, 2018, 91, 1157-1163.

93. Yang, J., Xu, T., Gomez, D. R., Yuan, X., Nguyen, Q., Jeter, M., Song, Y., Komaki, R., Hu, T., Hahn, S., Liao, Z. Nomograms incorporating genetic variants in BMP/Smad4/ Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Medicine 2018; 7(6):2247–2255.

94. Zhang, W., Shu, Q., Zhao, Z., Fan, J., Lyon, C. J., Zelazny, A., Hu, T.* Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. Clinical Proteomics 2018, 15:1.

95. Sun, D., Hu T.*. A low cost mobile phone dark-field microscope for nanoparticle-based quantitative studies. Biosensors & Bioelectronics. 2018, 99:513-518.

96. Sun, D., Hu, T.* A low cost mobile phone-based dark-field microscope for nanoparticle-based quantitative studies. Biosensors and Bioelectronics 2017, 15;99:513-518.

97. Fan, J., Zhang, H., Nguyen, D., Lyon, C. J., Mitchell, C. D., Zhao, Z., Graviss, E. A., Hu, T.* Rapid diagnosis of new and recurrent tuberculosis by quantification of circulating antigen in HIV-infected adults in the Greater Houston Metropolitan area: a retrospective cohort study. BMC Medicine 2017, 15:188.

98. Wu, B., Ouyang, Z., Lyon, C. J., Zhang, W., Clift, T., Bone, C., Zhao, Z., Kimata, J., Hu, T.* Plasma C4b peptide levels and HLA-B*57 genotype are associated with spontaneous HIV suppression in HIV-1-infected patients. ACS Infect. Dis. 2017, 3 (12): 880–885.

99. Liang, K., Wu, H., Hu, T., Li, Y. Mesoporous silica chip: enabled peptide profiling as an effective platform for controlling bio-sample quality and optimizing handling procedure. Clinical Proteomics.

2017, 13(1), 34.

100. Li, H., Yang, S., Yu, G., Shen, L., Fan, J., Xu, L., Zhang, H., Zhao, N., Zeng, Z. Hu, T., Wen, J., Zu, Y. Aptamer internalization via endocytosis inducing S-phase arrest and priming Maver-1 lymphoma cells for cytarabine chemotherapy. Theranostics. 2017, 7(5): 1204-1213.

101. “Circulating peptidome and tumor-resident proteolysis” Fan, J., Ning, B., Lyon, C., Hu, T.* Enzyme, edited by Dr. Tony Hu & Dr. Fuyu Tamanoi, 2017 Academic Press/Elsevier.

102. Book: Peptidomics of Cancer-Derived Enzyme Products, The Enzymes: Volume 42 edited by Dr.

Tony Hu & Dr. Fuyu Tamanoi, 2017 Academic Press/Elsevier.

103. Sun, D., Fan^, J., Liu, C., Liu, Y., Bu, Y., Lyon, C. J., Hu, T.* A noise reduction method for quantifying nanoparticle light scattering in low magnification dark-field microscope far-field images.

Anal. Chem. 2016, 88(24): 12001-12005.

104. Li, Y., Hu, T.* Decoding the Blood Peptidome as a New Biomarker Resource for Cancer Detection.

MOJ Proteomics Bioinform. 2016, 3(5):00099.

105. Wang, J., Dong, A., Liu, G., Anderson, G.J., Hu, Y., Shi, J., Hu, T., Nie G. Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay. Sci. Rep. 2016, 6:34252.

106. Zhu, L., Olsen, R., Horstmann, N., Shelburne, S., Fan, J., Hu, T., Musser, J. Intergenic VNTR Polymorphism Upstream of rocA Alters Toxin Production and Enhances Virulence in Streptococcus pyogenes. Infect. Immun. 2016, 84(7): 2086-93.

107. Qian, X., Nguyen, D.T.M., Li, Y., Lyu, J., Graviss, E.A., Hu, T.* Predictive value of serum bradykinin and desArg⁹-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: A retrospective case series. Tuberculosis. 2016, pii: S1472-9792 (16): 30407-3.

108. Mi, Y., Mu, C., Wolfram, J., Deng, Z., Hu, T., Liu, X., Blanco, E., Shen, H., Ferrari, M. A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis. Adv Healthc Mater. 2016, Apr; 5(8): 936-46.

109. Ma, X., Chong, L., Tian, R., Shi, R., Hu, Y., Ouyang, Z., Xia, Y. Identification and quantitation of lipid C=C location isomers: a shotgun lipidomics approach coupled with photochemical reaction. Proc.

Natl. Acad. Sci. U S A. 2016,113 (10): 2573-8.

110. Fan, J., Tea, M., Ma, L., Meng, Q., Hu, T. *, Singer, C., Ferrari, M. * Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer. J Proteomics Res 2016, 15(5): 1534-45.

111. Ren, Y., Wang, R., Gao, L., Li, K., Zhou, X., Guo, H., Liu, C., Han, D., Tian, J., Ye, Q., Hu, T., Sun, D., Yuan, X., Zhang, N. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy, Journal of Controlled Release. 2016, 228(28): 74-86.

112. Du, Y., Hu, T., Xia, Y., Ouyang, Z. Power Normalization for Mass Spectrometry Data Analysis and Analytical Method Assessment. Anal. Chem., 2016, 88 (6), pp 3156–3163.

113. Huang, H., Tao, L., Liu, F., Ji, L., Hu, T., Cheng, M., Chen, P., Akinwande, D. Chemical-Sensitive Graphene Modulator with Memory Effect for Internet-of-Things Applications. Nature: Microsystems & Nanoengineering 2016, 2:16018.

114. Khaled, S. Z., Cevenini, A., Yazdi, I. K., Parodi, A., Evangelopoulos, M., Corbo, C., Scaria, S., Hu, T., Haddix, S. G., Corradetti, B. Salvatore, F., Tasciotti, E. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA. Biomaterials 2016, 87:57-68.

115. Deng, Z., Li, Y., Fan, J., Wang G., Li, Y., Zhang Y., Cai G., Shen, H., Hu, T.* Circulating Peptidome to Indicate the Tumor-resident Proteolysis. Scientific Reports. 2015, 5:9327.

116. Wang, J., Liu, G., Xu, Z., Dai, J., Song, P., Shi, J., Hu, T., Hu, Z., Nie, G., Chan, Y., Zhao, Y. Hepcidin levels in hyperprolactinemic women monitored by nanopore thin film based assay:

Correlation with pregnancy-associated hormone prolactin. Nanomedicine: NBM. 2015, 11(4): 871-878.

117. Xu, Q., Hu, T.* Circulating peptidomics: a promising approach for the diagnosis and treatment of human cancers. Clin. Lab. Inter. 2015; April.

118. Zhang, P., Wei, Y., Wang, L., Debeb, B. G., Yuan, Y., Zhang, J., Yuan, J., Wang, M., Chen, D., Sun,

Y., Woodward, W. A., Liu, Y., Dean, D. C., Liang, H., Hu, T., Ang, K. K., Hung, M. C., Chen, J., Ma,

L. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1, Nature Cell Bio. 2014, 16(9): 864-875.

119. Zhang, P., Wang, L., Rodriguez-Aguayo, C., Yuan, Y., Debeb, B. G., Chen, D., Sun, Y., You, M. J., Liu, Y., Dean, D. C., Woodward, W. A., Liang, H., Yang, X., Lopez-Berestein, G., Sood, A. K., Hu, T., Ang, K. K., Chen, J., Ma, L. miR-205 acts as a tumor radiosensitizer by targeting ZEB1 and Ubc13, Nature Communications. 2014, 5:5671.

120. Li, Y., Li, Y., Chen, T., Kuklina, A. S., Bernard, P., Esteva, F. J., Shen, H., Hu, T.* Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer. Clin. Chem. 2014, 60(1): 233-242. PMID: 24146311.

121. Zhao, H., Li, Y., Hu, T. * Nanotechnologies in Glycoproteomics. Clin. Proteomics. 2014, 11:21.

122. Fan, J., Niu, S., Dong, A., Shi, J., Wu, H. J., Fine, D. H., Tian, Y., Zhou, C., Liu, X., Sun, T., Anderson, G. J., Ferrari, M., Nie, G., Hu, T. *, Zhao, Y. * Nanopore Film based Enrichment and Quantification of Low Abundance Hepcidin from Human Bodily Fluids. Nanomedicine: NBM. 2014; 10(5): 879-888. (Highlighted by Science Translational Medicine)

123. Wu, H. J., Li, Y., Fan, J., Deng, Z., Hu, Z., Liu, X., Graviss, E. A., Ma, X., Hu, T.* Antibody-Free Detection of M. tuberculosis Antigen Using Customized Nanotraps. Anal. Chem. 2014; 86 (4), pp 1988–1996. DOI: 10.1021/ac4027669

124. Shah, P., Zhu, X., Chen, C., Hu, T., Li, C. Z. Lab-on-chip device for single cell trapping and analysis. Biomed. Microdevice. 2014; 16(1): 35-41.

125. Huang H., Zhao P., Chen P., Ren Y., Liu X., Hu T., Akinwande D. RFID Tag Helix Antenna Sensors for Wireless Drug Dosage Monitoring. Translational Engineering in Health and Medicine, IEEE Journal of, 2014, 2(1): 1-8.

126. Wang Z., Wu H. J., Fine D., Schmulen J., Hu T., Godin B., Zhang J. X., Liu X. Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. Lab Chip. 2013, 2879-2882.

127. Srinivasan S., Alexander J. F., Driessen W. H., Leonard F., Hu T., Liu X., Arap W., Pasqualini R., Ferrari M., Godin B. * Bacteriophage Associated Silicon Particles: Design and Characterization of a Novel Theranostic Vector with Improved Payload Carrying Potential. J. Mater. Chem. B, 2013, 1:5218-5229.

128. Fan J., Huang Y., Finoulst I., Wu H. J., Deng Z., Xu R., Xia X., Ferrari M., Shen H., Hu T.* Serum Peptidomic Biomarkers for Pulmonary Metastatic Melanoma Identified by means of a Nanopore-based Assay. Cancer Letters. 2013. Nov 27. pii:S0304-3835(12)00658-1.

129. Fine D., Grattoni A., Goodall R., Bansal S. S., Chiappini C., Hosali S., van de Ven A. L., Srinivasan S., Liu X., Godin B., Brousseau L., Yazdi I. K., Fernandez-Moure J., Tasciotti E., Wu H. J., Hu T., Klemm S., Ferrari M. Silicon Micro- and Nanofabrication for Medicine. Adv. Healthcare Mater. 2013; 2192-2659.

130. Grattoni A., Tasciotti E., Fine D., Fernandez-Moure J. S., Sakamoto J., Hu T., Weiner B., Ferrari M., Parazynski S. Nanotechnologies and Regenerative Medical Approaches for Space and Terrestrial Medicine. Aviat Space Environ Med. 2013 Volume 83, No. 11 pp 1-12.

131. Fan J., Deng X., Gallagher J. W., Huang H., Huang Y., Wen J., Ferrari M., Shen H., Hu T.* Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Phil. Trans. A RSC 2012, 1967:2433-2447.

132. Fan J., Gallagher J. W., Wu H. J., Landry M. G., Sakamoto J., Hu T.* Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery. J Vis Exp 2012 (62): e3876.

133. Zhang, W., Rosano-Ortega, G., Hu, T., Bai, L., Qin, L. “New Investigation in PVP-Mediated Synthesis of Noble Metallic Nanomaterials” J. Nanosci. Nanotechnol. 2012; 12(3): 2634-2639.

134. Grattoni, A., Tasciotti, E., Fine, D., Fernandez-Moure, J., Sakamoto, J., Hu, T., Ferrari, M., Parazynski, S. * “Nanotechnologies and Regenerative Medical Approaches for Space and Terrestrial Medicine.” Aviation, Space, and Environmental Medicine. 2012; 83(11):1-12.

135. Huang H., Nieman K., Chen P. Y., Hu, T., Akinwande D. Properties and Applications of Electrically Small Folded Ellipsoidal Helix Antenna. IEEE Antennas and Wireless Propagation Letters, 2012, 11:678-681.

136. Sharma T^#, Hu T^#, Stoller M, Feldman M, Ruoff R S, Ferrari M, Zhang X. Mesoporous Silica as

Membrane for Ultra-Thin Implantable Direct Glucose Fuel Cells, Lab-on-a-chip, 2011, 11: 2460-2465. (# Shared first authorship)

137. Zhou M., Hu T., Ferrari M., Xie Z. Self-Assembled Zinc/Copper Hydroxide Carbonates with Tunable

Hierarchical Nanostructure, Journal of Nanotechnology and Nanoscience, 2011, 11: 1-5. (Cover story)

138. Hu T., Gopal A., Lin K., Peng Y., Tasciotti E., Zhang X., Ferrari M. High throughput enrichment of doi:10.1063/1.3528237 Small Proteins from Complex Biological Mixture Based on Porous Microchips. Biomicrofluidics, 2011, 5, 013410. doi:10.1063/1.3528237

139. Hu, T., Peng, Y., Lin, K., Shen, H., Brousseau, L.C., Sakamoto, J., Sun, T., Ferrari, M. Surface Engineering on Mesoporous Silica Chips for Enriching Low Molecular Weight Phosphorylated Proteins, Nanoscale, 2011, 3, 421-428.

140. “Cardiovascular nanomedicine: challenges and opportunities” Godin B., Hu T., La Francesca S.,

Ferrari M. Molecular & Translational Vascular Medicine, edited by Dr. Monte Willis & Dr. Jonathon Homeister, 2011 Humana Press.

141. “Morphology control of nanotextured drug carriers” Hu Y., Lin K.. Mass transport of nanocarriers, edited by Dr. Rita Sedra, 2011 Pan Stanford Publishing Pte. Ltd.

142. “Nanotechnology Towards Advancing Personalized Medicine” Sakamoto J. H., Godin B., Hu T., Blanco E., Van de Ven A, Vellaichamy A., Murphy M. B., La Francesca S., Schuenemeyer T., Given B., Meyn, A., Ferrari M. Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy, 2011 Pan Stanford Publishing Pte. Ltd..

143. Hu T., Bouamrani A., Tasciotti E., Li L., Liu X., Ferrari M. Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano. 2010 Jan 26; 4(1):439-451.

144. Bouamrani A.^#, Hu T.^#, Tascioti E., Li L., Chiappini C., Liu X., Ferrari M. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics. 2010 Feb; 10(3):496-505. (# Shared first authorship)

145. Hu T., Peng Y., Brousseau L., Bouamrani A., Liu X., Ferrari M. Nanotexture optimization by oxygen plasma of mesoporous silica thin film for enrichment of low molecular weight peptides captured from human serum. Science in China B. 2010, 53(11): 1-8.

146. Blinka E., Loeffler K., Hu T., Gopal A., Hoshino K., Lin K., Liu X., Ferrari M., Zhang J.X. Enhanced microcontact printing of proteins on nanoporous silica surface. Nanotechnology. 2010 Oct; 21(41):

415302.

147. Fan J., Yin J., Ning B., Wu X., Hu T., Ferrari M., Anderson G. J., Wei J., Zhao Y., Nie G. Direct evidence for catalase and peroxidase activities of ferritin-platinum nanoparticles. Biomaterials, 2010, 32(6): 1611-8.

148. Sakamoto J. H., van de Ven A. L., Godin B., Blanco E., Serda R. E., Grattoni A., Ziemys A.,

Bouamrani A., Hu T., Ranganathan S. I., DeRosa E., Martinez J. O., Smid C. A., Buchanan R. M., Lee S-Y, Srinivasan S., Landry M., Meyn A., Tasciotti E., Liu X., Decuzzi P., Ferrari M. Enabling individualized therapy through nanotechnology [review]. Pharmacol Res. 2010 Aug;62(2):57-89.

149. Hu T., Fine D. H., Tasciotti E., Bouamrani A., Ferrari M. Nanodevices in diagnostics [overview].

Wiley Interdiscip Rev [WIRES] Nanomed Nanobiotechnol. 2010 Mar 12.

C. Editorial Articles

150. Buriak, J., Hu, T. etc. Best Practices for Using AI when Writing Scientific Manuscripts. ACS Nano.

2023. In press.

151. Hu, T., Brinker J., Chan, W., Chen, C., Chen, X., Ho, D., Katada, K., Kotov, N., Liz-Marzan, L., Nel, A., Parak, W., Stevens, M. Publishing Translational Research of Nanomedicine in ACS Nano. ACS Nano. 2022, 16, 11, 17479-17481.

152. Hu, T., Chen, X. Nano for CRISPR. ACS Nano. 2022, 16, 6, 8505–8506.

153. Mulvaney, P., Buriak, J., Chen, X., Hu, T., Millstone, J., Stevens, M. Nanoscience and Entrep reneurship. ACS Nano. 2022, 16, 5, 6943-6944.

154. Liz-Marzán, L., Nel, A., Brinker, J., Chan, W., Chen, C., Chen, X., Ho, D., Hu, T., Kataoka, K., Kotov., N., Parak, W., Stevens, M. What Do We Mean When We Say Nanomedicine? ACS Nano 2022, 16, 9, 13257-13259.

155. Kotov, N., Akinwande, D., Brinker, J., Buriak, J., Chan, W., Chen, X., Chhowalla, M., Chueh, W., Glotzer, S., Gogotsi, Y., Hersam, M., Ho, D., Hu, T., Javey, A., Kagan, C., Kataoka, K., Kim, I., Lee,

S., Lee, Y., Liz-Marzán, L., Millstone, J., Mulvaney, P., Nel, A., Nordlander, P., Parak, W., Penner, R.,

Rogach, A., Salanne, M., Schaak, R., Sood, A., Stevens, M., Tsukruk, V., Wee, A., Voets, I., Weil, T., Weiss, P. ACS Nano. 2022, 16 (4), 4975-4976.

156. Hu, T. Can Sugarcoated Fingerprints be used to Identify Lurking Viruses? Proteomics. 2016, 16:

1947-1948.

157. Hu, T. Multidisciplinary Efforts Driving Translational Theranostics. Theranostics. 2014; 4(12):120912 10.

D. Patents Licensed (among 30 patents submitted and issued)

1. WO2011025602A1: Combinatorial multidomain mesoporous chips and a method for fractionation, stabilization, and storage ofbiomolecules (Licensed to Nanomedicine System Inc., Austin, TX).

2. WO2018151930A1: Compositions and methods of determining a level of infection in a subject (Licensed to Nanopin Technologies Inc., Phoenix, AZ)

3. US20190064178A1: Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry (Licensed to Nanopin Technologies Inc., Phoenix, AZ)

4. WO2019032824A1: Dark-field microscope apparatus utilizing portable electronic communication device (Licensed to Ares Diagnosis Co., San Jose, CA)

5. PCT/US2021/026436: Monocolnal antibodies and uses thereof (Licensed to Nanopin Technologies Inc., Phoenix, AZ)

6. WO2020252474A2: Detection ofantigens (Licensed to Nanopin Technologies Inc., Phoenix, AZ)

7. WO2018126043A1: Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples (Licensed to Ares Diagnosis Co., San Jose, CA)

8. Amplifiable nanoparticle enhanced quantitative scattering assay under low magnification dark field microscope (Licensed to Ares Diagnosis Co., San Jose, CA)

9. CRISPR-based assay for detecting SARS-CoV-2 in bodily fluids (Licensed to Nan opin Technologies Inc., Phoenix, AZ)

10. Method ofdetecting TB in blood (Licensed to Raisecare Technologies Inc., China)

11.Cu Growth Enhanced Plasmonic Assay for Isolation-free Exosome Analysis (Licensed to Raisecare Technologies Inc., China)

12. CRISPR-based Assay for detecting TB in serum (Licensed to Intelligenome LLC., New Orleans, LA)

13.Point-of-care on-Chip IGRA device and method for measuring SARS-CoV-2 Specific T cell activation (Licensed to Intelligenome LLC. New Orleans, LA)

14. Isolation-free, single-tube test for TB diagnosis and multi-drug resistance detection (Licensed to Intelligenome LLC. New Orleans, LA)

Active

R01 AI175618 Hu (PI) 04/01/2023 – 03/31/2028

NIH/NIAID

Title: Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood

Major goal: We propose to employ a novel CRISPR-based paper strip point-of-care assay to detect and quantify Mycobacterium tuberculosis-derived cell-free DNA (Mtb-cfDNA) in blood to simplify sample collection for the diagnosis and treatment evaluation of drug-sensitive and -resistent TB cases. Role: PI

2 R01 HD090927-07 Hu (PI) 05/01/2023-

04/30/2028

NIH/NICHD

Detecting pathogen and host factors on extracellular vesicles for pediatric TB diagnosis and management Our initial proposal developed a blood-based biomarker assay that read by a mass spectrometer that sensitively detects proteins release by M, tuberculosis (Mtb) to diagnosis TB even in diagnostically challenging pediatric populations, and we now intend to expand upon this experience to develop a streamlined assay that is read by an inexpensive portable device that can be used in resource-limited settings where TB is often prevalent. This assay will detect proteins on extracellular vesicle (EV) secreted by Mtb-infected phagocytes and by immune cells to evaluate Mtb burden and its containment by the immune system, and thus provide critical information about pathogen-host interactions required improve pediatric TB diagnosis and to allow rapid assessment of the effectiveness of TB treatment. Role: PI

R01 AI173021. Oberhelman, Hu (PI) 07/01/2023-06/30/2028

NIH/NIAID

Title: Diagnostic Innovations for Pediatric Tuberculosis in Bolivia

Major goal: We will alidate standard ranges of quantitative cfDNA established for clinical subgroups of children with TB disease or LTBI in an independent validation cohort. An additional aim will determine the correlation between quantitative cfDNA and quantitative imaging-based TB scores based on evidence of disease in the lung, the primary target organ in TB disease, by (1) chest radiograph, measured by computer-aided analysis using the CAD4TB v7 system, and by (2) lung ultrasound, performed with a portable/low-cost probe assisted by machine learning algorithms for automatic interpretation. Role: co-PI

1R01AI177986 Hu, Winthrop (PI) 04/01/2024 – 03/31/2029

NIH/NIAID

Title: CRISPR detection of circulating cell-free Mycobacterium avium complex (MAC) DNA for rapid diagnosis and monitoring of MAC pulmonary disease

Major goal: We seek to conduct analytic and clinical validation of a CRISPR-based blood test for MAC cellfree DNA as a measure of MAC pulmonary disease activity and treatment response. This biomarker could ultimately be used to guide diagnostic and therapeutic decision-making with regard to MAC pulmonary disease.

R01 AI144168 Hu (PI) 07/01/2022-06/30/2027

NIH/NIAID

A nanopore biosensor for leveling Mtb antigens in blood

Major goal: In this work, we propose to employ protein-based nanopore technology, which can recognize single peptide detection events to quantify two tuberculosis-specific biomarkers, to develop a portable diagnostic and treatment monitoring system for resource-limited areas. Based on our preliminary studies, we are confident that this diagnostic system will benefit the global tuberculosis control effort by improving early diagnosis and treatment monitoring of tuberculosis. Role: PI

1 U01 CA252965 Hu (PI) 10/1/2020-09/30/2025

NIH/NCI/NIBIB

Title: Digital Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples

Major goal: This proposal is designed to automate and further improve the accuracy and reproducibility of our novel assay with a single vesicle resolution for PC diagnosis, and perform analytical validation of this assay according to Clinical and Laboratory Standards Institute guidelines in CLIA-certified laboratory.

Role: PI

R01HD103511-01A1 Hu (PI) 05/01/2021-04/30/2026

NIH/NICHD

Title: Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHP

Major goal: We propose to develop a multiplex HIV and TB assay for improved detection and monitoring of HIV viral load and all stages of TB, from early infection to active TB disease, in young children suspected HIV and TB infections or HIV/TB co-infections. Role: PI

R21NS130542 Hu (PI) 08/01/2022- 07/31/2024

NIH/NIGMS

Title: Quantification of brain-derived extracellular vesicle microRNAs in blood by a liposome-mediated

CRISPR assay for traumatic brain injury detection

Major goal: We propose to employ a streamlined extracellular vesicles (EV) assay that can quickly measure miRNA signatures of brain cell-type-specific EVs directly from unprocessed plasma samples, and produce data to ensure diagnostic reliability. The proposed work will establish a new TBI diagnostic approach that will overcome current limitations and provide greater insight into the unique clinical effects of each patient suffering from TBI. Role: PI

R01AI179714-01 LaCourse (PI) 09/01/2023-

08/31/2028

Title: CRISPR-TB for pediatric TB diagnosis and treatment response

Major goals: The study will utilize samples from an ongoing large well-characterized cohort of children with suspected TB as well as additional cohorts of adults with confirmed TB and their asymptomatic household controls, and recently BCG-immunized asymptomatic infants to evaluate CRISPR-TB diagnostic performance, including longitudinal evaluation for treatment response, and extend evaluation to urine samples. Role: Co-Investigator, Site PI

P20GM109036 He (PI) 07/01/2022 - 06/30/2027

NIH/NIGMS

Title: Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases

Major goal: The overall objective of this COBRE Phase 2 application is to further develop and strengthen the clinical and translational research infrastructure at Tulane University and to continuously expand and support a critical mass of investigators with expertise in clinical and translational research in cardiometabolic disease. Role: Core Director, Site PI

R01 AI174964-01 Rodwell (PI) 09/01/2023-08/31/2028

NIH/NIAID

Rapid Detection of TB from Blood using Cell-Free DNA

Our goal is to transform TB diagnosis with a blood test that accurately distinguishes patients with TB disease from latent TB infection and other pulmonary disorders regardless of co- infection with HIV. Role: Co-Investigator, Site PI

1R01Al175315-01 Salgame, Song, Johnson (PI) 02/01/2023 – 01/31/2028 NIH/NIAID

Title: Biomarker Signatures of TB Infection in Young Children With and Without HIV

Major Goals: This proposal will test the hypothesis that a single orparsimonious combination of host, microbiologic and imaging biomarkers will meet or exceed the minimal TPP for a test of progression from infection to TB disease in children <5 years of age. Role: Co-Investigator, Site PI

R01AI162152 LaCourse (PI) 06/01/2021 – 05/30/2026

NIH/NIAID

Title: M. tuberculosis exosome detection for pediatric TB diagnosis

Major goal: We propose to use cryopreserved samples from well-characterized completed and prospective pediatric cohorts with high HIV-prevalence to efficiently evaluate Mtb-EV detection for pediatric TB diagnosis and treatment response and to adapt the assay for potential POC use. Role: Co-Investigator, Site PI

R01AI141500 Rodwell (PI) 10/1/2019-06/30/2025

NIH/NIAID

Title: An Antigen-Detection Blood Test for Tuberculosis

Major goal: The objective of our proposed study is to continue to improve the accuracy and usability of our prototype NanoDisk-MS assay for the detection of tuberculosis (TB) in blood samples. We will add a third antigen (Ag85B) to the assay, test our assay against well-characterized samples we have previously collected, and test our assay against prospectively enrolled patients in a high burden TB setting (Chisinau, Republic of Moldova), a medium burden TB setting (Monterrey, Mexico), and a low burden TB setting (San Diego,

California).

Role: Co-Investigator, Site PI

T32EB027632 Gaver (PI) 05/01/2019-04/30/2024

NIH/NIBIB

Title: Interdisciplinary Predoctoral Training in Bioinnovation

Major goal: The three Program Aims continue to be followed with the students in our BIOI program: 1). Trainees complete a translational biomedical research project with an emphasis on either imaging or transport processes that are fundamental to elucidating or manipulating physiological/cellular systems and are ripe for the creation of biomedical technologies. Scientific investigations will center on a) Imaging and Diagnostics, b) Regenerative Medicine, c) Biosensors for real-world applications, and d) Advanced Therapeutic Materials; 2). The curriculum educates trainees about scientific fundamentals, biomedical systems analysis, product conceptualization, analysis and design, entrepreneurship, IP and regulatory mechanisms, and market responses to innovation. This broad curriculum expands trainees’ career horizons: 3). The project reinforces a Bioinnovation community that emphasizes interdisciplinary interactions and will improve the Bioinnovation ecosystem in our region.

Role: Co-investigator and Mentor for the predoctoral students

Completed

W8IXWH1910926 Hu (PI) 09/30/2019-09/29/2024

DOD-ARMY: (USAMRAA)

Qualification of Circulating Mtb Antigens for Rapid TB Diagnosis and Treatment Monitoring

Major goal: The proposed study will develop and refine a rapid, point-of-care and inexpensive diagnostic tool that can sensitively diagnose active tuberculosis (TB), the leading cause of death from infectious disease. Role: PI

1 R01HD090927 Hu (PI) 03/01/2017-02/28/2024

NIH/NICHD

Title: Direct quantitation of the circulating Mtb-peptidome for pediatric TB management

Diagnosing pediatric tuberculosis (TB) and evaluating its timely response to therapy is extremely challenging, since it can be very difficult to obtain necessary samples, and these tend to have poor diagnostic value, but early detection is critical in reducing morbidity and mortality, while treatment monitoring may identify children who would respond better to novel treatment regimens minimizing side-effects and treatment duration. In this project we use a novel nanoparticle-based method to detect blood levels of two TB and one host-response protein released during active TB disease in order to diagnose and monitor pediatric TB using easy-to-obtain smallvolume blood samples. Based on our preliminary results, we are confident that this strategy has great potential to: 1) promote early detection of active pediatric TB to decrease progression and improve outcomes, and 2) permit rapid monitoring of pediatric TB therapy, which may allow physicians to personalize a child’s treatment to avoid unnecessary exposure to toxic TB drugs once the child has cleared their TB infection.

Role: PI

R01 AI113725 Hu (PI) 01/01/2015 – 12/31/2020

National Institute of Allergy and Infectious Diseases

Title: Real-time Detection of Active TB in HIV Exposed Children on Customized Nanotrap

The goal of this proposal is to implement a quantitative biomarker detection and monitoring platform that combines a sophisticated peptide-enriching nanotechnology procedure (“Nanotrap”), with the powerful capabilities of bench-top mass spectrometry (MS), without the use of complicated bacterial isolation procedures or antibodies to address the challenge in the field of active TB detection and control in HIV exposed children.

Role: PI

R01AI122932 Hu (PI) 03/01/2016-2/28/2021

National Institute of Allergy and Infectious Diseases

Title: Rapid Diagnostic Quantification of Circulating TB antigen for Treatment Evaluation

In this project, we implement a rapid nano-sensing platform that combines the sophistication of massproduced porous nanodisk fabrication, peptide-enrichment, and the powerful capabilities of a portable MS system specially developed for resource-limited area -- for detection and quantification of two TB-specific biomarkers in patients’ blood. Based on our preliminary studies, we are confident that this high-impact strategy could decrease the likelihood of disease progression, improve therapeutic regimens, and prevent the emergence of severe drug resistance strains. Role: PI

R21EB026347 Hu (PI) 09/18/2019-07/31/2021

NIH/ NIBIB

Mobile based Nanoplasmonic Quantification of Mtb-derived Exosomes in Serum for Pediatric TB diagnosis The major goal: We propose to explore a novel rapid, accurate, low-cost and easy-to-use mobile phone-based blood test for pediatric TB diagnosis in LMIC settings. Role: PI

R21 Al126361 Hu (PI) 07/01/2017-06/30/2020

National Institute of Allergy and Infectious Diseases

Title: Multiplexed quantification of circulating peptidomic signatures for EBOLA early diagnosis

In this proposal, we will implement a rapid nano-sensing and monitoring platform that combines the sophistication of mass produced porous nanodisk fabrication, peptide-enrichment, and the powerful capabilities of bench-top MALDI mass spectrometry – for detection and quantification of target blood peptides from an Ebola antigen viral matrix protein VP40 and two host serological proteins referring to the host response to EBOV infection. Successful completion of this proposed work will provide a novel technology that can overcome the significant hurdles of current diagnostic methodologies for Ebola and other infectious agents, potentially transforming the protocols for care, treatment, and containment of future epidemics.

Role: PI

R01AI137681-01 Catanzaro (PI) 06/01/2018 - 05/30/2024

NIH/NIAID

Title: Identifying individual risk of progression to active Tuberculosis

Major goal: We propose to develop a multimetric signature of host biomarkers that together will have a sensitivity and specificity of 90% for predicting progression to active TB in one year, a critical first step to developing cost-effective and ethical treatment plans in order to reach the World Health Organization goal of Ending TB by 2035.

Role: Co-Investigator, Site PI

ASU_Mayo seed fund Jelinek and Hu (PI) 01/01/2018 – 12/31/2018 Mayo Clinic

Title: Identification and Rapid Quantification of Myeloma Cell-Specific Extracellular Vesicles

The proposal is aim to apply nanoplamonic detection assay toward development of a sensitive test detecting Myeloma(MM)-derived micovesicles (MV). We will identify markers that will broadly capture all circulating MVs as well as identify MM-specific membrane proteins expressed on captured MVs, thereby enabling specific quantitation of MM-MVs in a complex MV population derived from a wide variety of tissues. Role: Principal investigator

ASU_Mayo seed fund Hu and Malhi (PI) 01/01/2018 – 12/31/2018 Mayo Clinic

Title: Developing nanotechnique-based diagnostics for obesity-associated liver disease using circulating hepatocyte-derived extracellular vesicle biomarkers

We propose that rapid and inexpensive analysis of liver-derived extracellular vesicles (EVs) in plasma could replace liver biopsy for Nonalcoholic fatty liver disease (NASH) diagnosis and that repeated EV assays could monitor disease progression and responses to therapy. We plan to use our existing nanoplasmonic (nPES) assay platform to quantify disease-stage-specific EV biomarkers in blood for rapid NASH diagnosis, using use plasma samples Dr. Alina Allen has collected from a well-characterized bariatric surgery cohort. Signal derived from our unique nPES biomarker assay should correlate with NASH severity. Role: Principal investigator

Title: NanoForest Microdevice for Exosomal Peptidomic Analysis

Date: 10/01/2014-09/30/2016

Identification number: U54CA151668 -Pilot

Sponsor: National Cancer Institute

Role: Principal Investigator

This proposal will focus upon developing a highly-integrated and micro/nano-technology based platform to efficiently extract and analyze the circulating exosome and exosomal peptides.

Title: Proteomic biomarker discovery for active myeloma

Date: 7/01/2015 – 12/31/2016

Identification name: Golfer Against Cancer Foundation Award

Sponsor: Golfer Against Cancer Foundation

Role: Principal Investigator

We aim to refine the peptidomic analysis in bone marrow of multiple myeloma patients for a better understanding of certain proteolytic events, particularly in the tumor microenvironment.

Title: Absolute Quantification of Pathologic Antigens using Nanopore-MS for diagnosing HIV/TB co-infection Date: 07/01/2015 – 06/30/2017 (expired due to the institutional change)

Sponsor: John S. Dunn Foundation

Role: Principal Investigator

Note: The award is to support us to 1. test the validity of this research platform on a larger number of blood samples (from a long-term National Institute of Allergy and Infectious Diseases (NIAID) study; and 2. determine if our TB blood test and detection model can effectively find and measure TB/HIV co-infection and monitor early TB treatment therapies on a global level.

Title: Nanopore-enabled peptidomics analysis to predict cardiotoxicity caused by anti-cancer chemotherapy Date: 06/01/2014-11/30/2016

Sponsor: Kostas Family Foundation

Role: Principal Investigator

Title: Identifying Biological Markers for Severe Depression

Date: 10/01/2014 – 09/30/2016

Sponsor: Virginia & Ernest Cockrell Award

Role: Principal investigator

Title: Development of in-vitro Nanodevice for Active TB Diagnosis

Date: 07/01/2014 – 06/30/2016

Sponsor: Cockrell Family Foundation

Role: Principal investigator

Title: Rapid Detection of Biomarkers from Human Body Fluids for Active Tuberculosis Diagnosis with Nanoporous silica chip

Date: 10/01/2011-12/31/01/2015

Identification number: 81XWH-11-2-0168-P1

Sponsor: Department of Defense

Role: Principal Investigator

The goal of this study is to combine surface chemistry modulation integrating of nanotechnology and develop a real-time detection and quantitative analysis device of M. tuberculosis specific antigen.

Title: Tailored Nanodevices to Understand Resistance Against HIV

Date: 11/01/2012 – 05/31/2014

Award name: Grand Challenges Explorations Round 9

Sponsor: Bill & Melinda Gates Foundation

Role: Principal Investigator

The goal of this proposal is to use highly innovative chip-based nanodevices to identify novel biomarkers reflecting the multifactorial processes that trigger potent HIV-1 suppression. Dissecting these unique molecular signatures may enable us to design and develop improved clinical strategies for enhancing host resistance against HIV-1.

Title: Texas Center for Cancer Nanomedicine

Date: 09/01/2010-07/31/2015

Identification number: U54CA151668

Sponsor: National Cancer Institute

Principal investigator: Sood A., Gorenstein D.

Role: Co-director, co-investigator

Percent effort: 25%

Project 1. Co-investigator (10%)

Project 3. Co-investigator (5%) Core 3. Co-Director (10%)

This center grant aims to utilize innovative nanotechnologies for new therapeutic strategies, methods for monitoring outcomes, early diagnosis and prevention protocols for ovarian and pancreatic cancers.

Title: Personalization of cancer therapy using nanotherapeutics

Date: 08/01/2013-07/31/2015

Identification number: U54CA143837 Extension

Sponsor: National Cancer Institute Role: Co-Principal Investigator

This research aims to level the accumulation of PLD to tumors in various mouse models and correlate with its therapeutic efficacy.

Teaching

2000 – 2001	Optical Chemistry	Tsinghua University
2003 – 2004	Physical Chemistry I	The Univ. of Texas at Austin
2004 – 2005	Physical Chemistry II	The Univ. of Texas at Austin
2005 – 2007	General Chemistry	The Univ. of Texas at Austin
2012 – 2013	Nanomedicine Workshop	Houston Methodist Research Institute
2016 – 2017	Fundamentals of Biomedical Engineering	Arizona State University
2018 – 2019	Thermodynamics (I&II)	Arizona State University
2018 – 2019	Engineering Perspectives on Biological Systems	Arizona State University
2018 – 2019	Fundamentals of Biomedical Engineering	Arizona State University
2019 – 2019	Biosensing TechnologiesArizona	State University
2019 – 2022	Molecular Medicine	Tulane University

Advisees

Name	Title	Period in Hu’s lab	Present position
Jia Fan, M.D., Ph.D.	Postdoc	05/2011-08/2019	Assistant professor, Department of Biochemistry and Molecular Biology, Tulane University, USA
Hung-jen Wu, Ph.D.	Postdoc	11/2011-02/2014	Associate Professor, Department of Chemical Engineering, Texas A&M University, USA
Bo Ning, Ph.D.	Research Scientist	05/2017-08/2019	Assistant professor, Department of Biochemistry and Molecular Biology, Tulane University, USA
Chang Liu, Ph.D.	Postdoc	07/2013–07/2018	Associate Professor, Department of Chemical Engineering, University of South Carolina
Dali Sun, Ph.D.	Postdoc	07/2015-08/2018	Assistant Professor, Department of Biomedical Engineering, North Dakota State University
Yu Huang, Ph.D.	Postdoc	05/2014-07/2016	Assistant Professor, Department of Biomedical Engineering, Utah State University
Meihua Wan, M.D. Ph.D.	Postdoc	04/2019-12/2018	Professor and Chief Physician, West China Medical College of Sichuan University
Christopher Lyon, Ph.D.	Research Scientist	02/2016-08/2019	Assistant Professor, Department of Biochemistry and Molecular Biology, Tulane University, USA
Xuerong Chen	Visiting Scholar	06/2018-08/2018	Professor, Department of Respiratory Medicine, West China Medical College of Sichuan University
Meryl Rodrigues	Graduate Student	12/2016-08/2019	Scientist, Abbott Rapid Diagnostics Company, USA
Inez Finoulst, Ph.D.	Postdoc	05/2011-09/2013	Quality Engineer Production CAF-DCF Consultant, Belgium
Yunlong Zhou, Ph.D.	Postdoc	05/2013-10/2014	Professor, Wenzhou Medical University, China
Fei Liu, Ph.D.	Postdoc	08/2013-01/2015	Professor, Wenzhou Medical University, China
Yueguo Li, M.D., Ph.D.	Postdoc	07/2012-01/2014	Professor and Deputy Chair, Department of Pathology, Tianjin Tumor Hospital, China
Jinling Zhang. M.D.	Postdoc	02/2013-09/2013	Professor and Vice Chair, Department of Gynecology, Shenzhen People’s Hospital, China
Yang Liu, M.D.	Postdoc	07/2015–06/2020	Professor, Department of Gastroenterology, Tianjin Tumor Hospital, China

Yajun Gu, Ph.D.	Postdoc	11/2014-12/2015	Associate Professor, Tianjin Medical University
Zaian Deng, Ph.D.	PhD student	05/2012-06/2015	Associate Professor, Chinese Academy of Science, Wenzhou Biomaterial Institute, China
Kai Liang, Ph.D.	Postdoc	05/2012-03/2015	Assistant Professor, Institute of Biophysics, Chinese Academy of Science, China
Boyue Wu, Ph.D.	Postdoc	08/2016-08/2017	Associate Professor, Tianjin Medical University, China
Tanxi Cai, Ph.D.	Postdoc	12/2016-12/2018	Associate Professor, Institute of Biophysics, Chinese Academy of Science, China
Xiangxing Kong, Ph.D.	Research Associate	05/2017-now	Senior Research Associate, Tulane University
Jeffery Sun	Student	06/2015-05/2016	Graduate student, UC Berkeley
Kevin Lin	Student	02/2011-07/2013	M.D. student, Duke University
Paul S. Bernard	Student	05/2013-09/2013	M.D. student, Texas A&M University
James W. Gallaher	Student	05/2011-09/2012	M.D. student, The university of Texas Medical School
Qingbo Shu, Ph.D.	Postdoc	01/2016-now	Postdoc Fellow, Tulane University
Lingpeng Zhan, Ph.D.	Postdoc	05/2013-now	Associate Member, Shenzhen Bay Lab
Tori Clift	Student	05/2014-08/2014	Graduate student, Purdue University
Samantha M. Rodriguez	Student	05/2013-08/2013	Graduate student, Texas Tech University
Margaret Johnson	Student	05/2013-08/2013	Graduate student, The Univ. of Texas at Austin
Chris Bone	Student	05/2014-06/2015	M.D. Student, Mississippi University
Alexander Roesler	Student	05/2014-09/2014	M.D. student, Duke University
Anna S. Kuklina	Student	05/2013-09/2013	Undergraduate student, The Univ. of Texas at San Antonio
Michael Peng	Student	06/2015-05/2016	Undergraduate student, The Univ. of Texas at Austin
Hu Zhao	Student	05/2012-10/2013	Graduate student, Chinese Academy of Science, China
Michele Qian, Ph.D.	Postdoc	05/2014-12/2016	Professor, Wenzhou Medical University, China
Yang Bu,	Graduate Student	03/2015-11/2016	Graduate Research Assistant, Hongkong Technical University
Zhiyi Liu, Ph.D.	Postdoc	05/2015-05/2016	Research Associate, The Univ. of Texas M.D. Anderson Cancer Center
Kuldeep Giri	Postdoc	09/2022-now	Postdoc fellow, Tulane University
Fangfang Zhang	Postdoc	05/2017-08/2019	Physician, Tianjin Tumor Hospital
Weiwei Jiao, Ph.D.	Postdoc	06/2017-12/2018	Physician, Beijing Children Hospital
Pouya Amrollani	Graduate Student	11/2017- 06/2020	Graduate Research Assistant, Arizona State University
Yushuo Liang	Student	08/2017 – 12/2018	Graduate Research Assistant, Arizona State University
Sarah Spiegel	Research Assistant	08/2017 – 03/2019	Research assistant, NIH
Regan Huish	Student	05/2017-07/2019	Undergraduate Research Assistant, Arizona State University
Resee Huish	Student	04/2017-07/2019	Undergraduate Research Assistant, Arizona State University
Jesse Yepiz	Student	03/2017-07/2019	Undergraduate Research Assistant, Arizona State University
Jaffalie Twaibu	Student	03/2017-07/2019	Graduate Research Assistant, Arizona State University
Nichole Richardson	Student	07/2017-07/2019	Undergraduate Research Assistant, Arizona State University
Robert Walls	Student	07/2018-07/2019	Undergraduate Research Assistant, Arizona State University
Flore Herve, Ph.D.	Postdoctoral fellow	08/2021 - now	Tulane University School of Medicine
Sudipa Maity, Ph.D.	Postdoctoral fellow	06/2021 - now	Tulane University School of Medicine
Wenshu Zheng, Ph.D.	Postdoctoral fellow	08/2018 - now	Tulane University School of Medicine
Shu Wang, Ph.D.	Postdoctoral fellow	08/2018 - now	Tulane University School of Medicine
Qingbo Shu, Ph.D.	Postdoctoral fellow	11/2016 - now	Tulane University School of Medicine
Sutapa Chandra	Postdoctoral fellow	11/2021 - now	Tulane University School of Medicine
Li Yang, Ph.D.	Postdoctoral fellow	08/2019 - now	Tulane University School of Medicine
Jiayi Huang, Ph.D.	Postdoctoral fellow	08/2018 – 04/2020	Wiley Publisher
Zhen Huang, Ph.D.	Postdoctoral fellow	11/2019 – 11/2021	Associate Professor, The Third Hospital in Shenzhen, China
Shan Liu, M.D.	Visiting scholar	02/2020 – 11/2021	Associate Professor, Sichuan People Hospital, China
Jing Wu, Ph.D.	Visiting scholar	08/2019 – 03/2020	Vice chair, department of pathology, Tianjin 3rd Hospital, China
Liyan Mao	Visiting scholar	09/2018 – now	Research associate, Wuhan Tongji Hospital, China
Brady M Youngquist,	Graduate Student	01/2020 – now	Tulane University School of Medicine
Chandler Monk	Graduate Student	09/2020 – now	Tulane University School of Medicine
Duran Bao	Graduate Student	08/2020 – now	Tulane University School of Medicine
Julian Saliba	Graduate Student	08/2021 – now	Tulane University School of Medicine

Consultantships

11/01/2013 – 10/30/2014 Department of Infectious Disease The Univ. of Texas Medical Branch

External Consultant on an internal grant “Circulating proteomic profile of West Nile virus”

Awards and Honors

2009 Scholar Development Award, UT Austin

2012 President Award for Transformational Excellence, Houston Methodist Research Institute

2013 Virginia and Ernest Cockrell Junior Faculty Award

2013 Golfer Against Cancer Award

2014 Kostas Cardiovascular Nanomedicine Award

2015 Methodist Cornerstone Award

2015 MSACL Young Investigator Award

2016 John S. Dunn Foundation Award

2016 Translational Research Initiative Award

2018 Arizona Young Investigator Award

2018 NACCCA 2018 Outstanding Research Award

2019 William J. Dorsen Jr. Outstanding Research Award

2020 NACCCA Innovation Award

2021 Tulane Faculty Award in Basic Research

2021 University Innovation Award, Tulane University

2022 Synergy Award, Tulane School of Medicine

2023 University Galaxy Award, Tulane University

2024 Entrepreneurship Award, Tulane University

2025 George Adrouny Memorial Lectureship

2025 Tan Chin Tuan Fellowship (Senior Inbound), Nanyang Technological University in Singapore

2025 The Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research, American Association of Clinical Chemistry (AACC)

Honors by Trainees

2016 Dr. Hung-Jen Wu (Former postdoc), Kaneka Junior Faculty Award

2017 Dr. Chang Liu (Postdoctoral fellow), K21 awarded by NIH/NIAID

2019 Robert Walls, graduate with honor, Arizona State University

2021 Dr. Sudipa Maity, recipient of Jim and Betty Karam Postdoctoral Training Endowed Fund

2022 Lane Pierson, graduate with honor, Tulane University

2022 Dr. Chang Liu (Former postdoc), NSF career award

2023 Dr. Dali Sun (Former postdoc), NSF career award

2024 Dr. Chang Liu (Former postdoc), NIH director award

Invited Talks, Panels (2011-2025)

1. Nanoplasmonic enhanced Raman AI profiling for inherited metabolic disorder in newborns. ACS Spring 2025, March 23-27, 2025, in San Diego, CA.

2. Light-reversible nanorobot enables high-purity isolation of extracellular vesicles from biofluids. ACS Spring 2025, March 23-27, 2025, in San Diego, CA.

3. Sensitive blood-based detection of HIV-1 and Mtb peptides for disease diagnosis by Immuno-Affinity LC-MS. ACS Spring 2025, March 23-27, 2025, in San Diego, CA.

4. Detect the undetectable using Nanotechnology with AI. The 7^th West China Clinical Laboratory Meeting. Dec. 13-15, 2024. Chengdu, China.

5. Unveiling the Microscopic Mysteries: Advancing TB Detection and Beyond. The 18th ASEAN Conference of Clinical Laboratory Sciences. Nov. 21-23, 2024. Brunei.

6. Micro-assays for personalized diagnosis through targeted multi-omics. The 8^th Chinese Society of Extracellular Vesicles Annual Meeting. Nov. 15-17, Guangzhou, China.

7. Multi-omics analysis in EV enables personalized diagnosis. American Association of Extracellular Vesicles (AAEV) annual meeting. Nov. 10-13, 2024. Houston, TX.

8. Assessing Light-Reversible Microswimmer Particles to Enable High-Purity & Low-Cost Isolation of Extracellular Vesicles from Biofluids. 6th Exosome-Based Therapeutics Development Summit. Sept. 17-19, 2024. Boston, MA.

9. Plenary Speech:EV-based omics analysis enabling personalized diagnosis.The 8th Frontier and Translation Conference on Extracellular Vesicles. Aug. 24-25, 2024. Chengdu, China.

10. Multi-Omics Analysis of Pathogen-Host Interactions Enables Personalized Diagnosis of Diseases. Clinical Translational Science Division Meeting, ADLM Annual Meeting 2024. Jul. 30, 2024. Chicago, MI.

11. Plenary Speech:Multi-omics study in extracellular vesicles for understanding TB pathogen-host interaction. The 2nd Annual Conference of the Specialized Committee on Immunodeficiency Monitoring and Translation. July 13, 2024. Tianjin, China.

12. EV-based omics analysis enabling personalized diagnosis. Wisdom Symposium 2024. July 8, 2024. Seoul, Korea.

13. Detecting the undetectable with AI-enabled nanotechnologies. Nano Korea 2024, July 4, 2024. Goyang, Korea.

14. Precision Diagnosis of Tuberculosis: Empowering Personalized Healthcare with Nano and Micro Technologies. The 22^nd International Nanotech Symposium and Exhibiton. July 3, 2024. Sungkyunkwan University, Korea.

15. Life in a bubble – Multi-omics study in extracellular vesicles. KAIST Emerging Material Symposium. July 1-2, 2024. Suwon, Korea.

16. Nano and Micro Technologies in TB Personalized Healthcare. APRC 2024, April 26-29, Taipei, Taiwan.

17. Becoming smaller, faster, and more inclusive – point-of-care testing assays for TB detection. GRAfT Consortium 10 year Anniversary Conference. March 20-22, 2024. Virginia, US.

18. EV-based Omics Analysis Enabling Personalized Diagnosis. SelectBIO In vitro diagnostics meeting. March 17-19, 2024. Rotterdam, Netherlands.

19. Empowering Personalized Healthcare with Nano and Micro Technologies. Centre for Craniofacial and Regenerative Biology, King’s College London. March 14, 2024. London, UK.

20. Life in a Bubble. 2024 Pittcon conference. Feb. 25-28, 2024. San Diego, CA.

21. Precision Diagnosis of Tuberculosis. 2^nd International Virtual Conference on Mycobacterium tuberculosis Research and Drug Development. Feb. 27-28, 2024.

22. Nanoplasmonic Quantification of Pathogen-derived Extracellular Vesicles for Personalized Diagnosis of Diseases. The 7^th Aggregate Global Webinar. Nov. 29, 2023.

23. Talks at The Union World Conference on Lung Health 2023. Nov. 15-18, 2023. Paris, France.

a) IGRA-on-a-chip enables a rapid TB detection. Session: Role of Immunology in the TB diagnosis.

b) Nanoplasmonic-enhanced immunoassays to detect MTB-derived extracellular vesicles in blood for TB diagnosis. Session: TB Diagnostics, including drug-resistance determination: Technical aspects and new developments.

c) Portable, battery-operated lab-in-tube detection of active TB and drug-resistance. Session: New Diagnostics in DRTB.

d) Rapid differentiation of Mycobacteria at sub-species resolution by an antigen-peptidome algorithm. Session: NTM infection a new challenges.

24. Keynote: EV-based Omics Analysis Enabling Personalized Diagnosis. NUS-THU Joint Workshop on Biomedical Engineering 2023. Oct. 2-3, 2023. National University of Singapore, Singapore.

25. Precision Diagnosis of Tuberculosis: Empowering Personalized Healthcare with Nano and Micro Technologies. Sept. 26, 2023. Department of Pathology, University of California San Diego. San Diego, CA.

26. Life in a bubble – Multi-omics study in extracellular vesicles. Aug. 26-28, 2023. The 5^th China Nano Conference. Beijing, China.

27. Multi-omics biomarker discovery for precision TB diagnosis. July 12, 2023. The Chinese University of Hongkong. Hong Kong.

28. An unfolding story of molecular analysis for personalized diagnosis of TB. June 15, 2023. Taipei Medical University. Taipei, Taiwan.

29. Peptidomic classification of Mycobacterial at sub-species resolution. April 3-7, 2023. MSACL conference. Monterey, CA.

30. Identifying novel biomarkers on extracellular vesicles for rapid disease diagnosis. March 18-22, 2023. Pittcon Conference. Philadelphia, PA.

31. Probing Life in Bubbles. The Meeting of Extracellular Vesicles 2022. Dec. 12-14. Los Angeles, CA.

32. Nanoplasmonic Quantification of Pathogen-derived Extracellular Vesicles in Blood. Dec. 15, 2022. UCLA, Los Angele, CA.

33. A Standalone Lab-in-a-Tube Multiplex Assay for Rapid TB Drug-Susceptibility Testing. December 4-7, 2022. Banff, AB, Canada.

34. Quantification of circulating cell-free DNA for pediatric TB diagnosis. The Union – World Conference of Lung Health 2022. Nov. 8-11, 2022. On-line Virtual.

35. Detecting the undetectable with Al-enabled nanotechnology. Bio on the Bayou. Nov. 1-2, 2022. New Orleans, LA.

36. Keynote Speech: Roadmap to Independence. 2022 IM Scholarship Day. Nov. 1, 2022. New Orleans, LA.

37. New diagnostic approaches to NTM---can we diagnose infection without sputum and monitor treatment success? 2022 NTM Research Consortium Meeting. Oct. 27-29, 2022. Portland, OR.

38. Nano-assays to decode the biosignatures in blood. Department of Pathology, Johns Hopkins University. Oct. 25, 2022. Baltimore, MD.

39. Nano-assays to decode the biosignatures in blood. Department of Pathology at the University of Texas Southwestern Medical School. Oct. 13, 2022. Dallas, TX.

40. Detection of pathogen-derived extracellular vesicles and their application in disease diagnosis. The 5^th China-ASEAN Medical Education Forum on Medical Imaging and Basic Medicine. Aug. 27, 2022. Online Virtual.

41. Decoding blood signatures for pathogen detection at sub-species resolution. NIH Clinical Center. Jul. 14, 2022. Bethesda, MD.

42. Probing the life in bubbles – Nanoplasmonic Quantification of pathogen-derived Extracellular vesicles in blood. Hilton Head Solid-state sensors, actuators and microsystems workshop. June 5-9, 2022. Hilton Head Island, SC.

43. Nanoplasmonic Quantification of Pathogen-Derived Extracellular Vesicles in Plasma Microsamples. AICHE Annual Meeting 2021. Nov. 8-11. Boston, MA.

44. Liposome-mediated Detection of SARS-CoV-2 RNA-positive Extracellular Vesicles in Plasma. BMES Annual Meeting 2021. Oct. 6-9, 2021. Orlando, FL.

45. Detection of Infectious Disease at Species Resolution with Pathogen-derived Peptidomes. AACC Annual Meeting 2021. Sept. 26-30, 2021. Atlanta, GA.

46. Keynote Talk. 2021 Research Experience Symposium. Tulane University Department of Chemical Engineering. Aug. 6, 2021. New Orleans, LA.

47. Written in Blood. Rice BioE colloquium, April 20, 2021. Rice University, Houston, TX.

48. Nanotechnology-Enabled Biomarker Discovery for Personalized Diagnosis. Kate Gleason College of Engineering, Rochester Institute of Technology. February 25, 2021.

49. Detection of Infectious Disease at Species Resolution with Pathogen-derived Peptidomes. Louisiana State University Health Science Center. February 9, 2021.

50. Spinning Biological Trash into Diagnostic Gold. Division of Pathology and Laboratory Medicine’s Ground Rounds at the University of Texas MD Anderson Cancer Center. February 6, 2021

51. Mobile-based Nanoplasmonic Quantification of Mtb-derived Exosomes in Serum. NACCCA 40^th Anniversary Virtual Meeting. December 16, 2020.

52. Quantitative and Ultra-Sensitive Saliva Test with Cellphone for COVID-19. AIChE Annual Meeting. November 16-20, 2020.

53. Sensitive tracking of viral RNA through SARS-CoV-2 infection stages. Louisiana COVID-19 Seminar Series. Oct. 15, 2020.

54. Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years.

The 50th Union Conference -TB Science 2020 Virtual conference. Oct. 20-24, 2020.

55. Mycobacterium antigen peptidome enables a rapid differentiation of species and sub-strains. ASMS Virtual conference. June 1, 2020.

56. Blood-based antigen test for rapid TB diagnosis. CTVD 6th Annual Virtual Meeting. June 16-17, 2020.

57. Written in blood. North Carolina State University. Jan 10, 2020. Raleigh, NC.

58. Rapid differentiation of Mycobacterium using antigen peptidome. 2019 NTM Research Consortium. Nov. 14-16, 2019. Portland, OR.

59. Mass spectrometry-based assay for rapid mycobacterium detection and differentiation. The 7^th Sichuan Provident TB conference. Nov. 8-10, 2019, Chengdu, China.

60. Blood-based antigen test for rapid TB diagnosis. The 50^th Union World Conference. Oct. 27-Nov. 1, 2019. Hyderabad, India.

61. Rapid differentiation of Mycobacterium using antigen peptidome. China Non-tuberculosis Mycobacterium Conference. Oct. 19-21, 2019. Hangzhou, China.

62. Quantum Dots-enabled rapid quantification of biomarker on a single extracellular vesicle. ACS 2019 annual meeting. Aug 25-28, 2019. San Diego, CA.

63. Mass spectrometry-based assay for rapid mycobacterium detection and differentiation. Guizhou CDC. Aug 21, 2019. Guiyang, China.

64. Nanoplasmonic quantification of extracellular vesicles in microsample. ChinaNano 2019. Aug. 17-19, 2019. Beijing, China.

65. Mass spectrometry-based assay for rapid mycobacterium detection and differentiation. AACC 2019 annual meeting. Aug. 6-9, 2019. Anaheim, CA.

66. Quantification of antigen peptidome enables the rapid differentiation of Mycobacterium. Lymph Forum 2019. May 30-June 2, Austin, TX.

67. Quantification of Circulating Extracellular Vesicles for Rapid Diagnosis. Nature Biomedical Engineering Conference. Mar. 21-24, 2019. Nanchang, China.

68. Profiling of Blood-based Mycobacterium Antigen Peptides for Rapid Diagnosis. The 2^nd International Tuberculosis Forum. Mar 15-17, 2019, Shanghai, China.

69. Spinning Biological Trash into Diagnostic Gold. Tulane University. Feb. 7, 2019. New Orleans, LA.

70. Nanotechnology-enabled Biomarker Discovery. University of Michigan. Jan. 8, 2019. Ann Arbor, MI.

71. Circulating Peptidome and Tumor-Resident Proteolysis. The 5^th People’s Hospital in Suzhou. Dec. 18, 2018. Suzhou, China.

72. Spinning Biological Trash into Diagnostic Gold. Chongqing Children Hospital. Dec. 15, 2018. Chongqing, China.

73. Midas Touch by Small Particles. West China Medical Institute by Sichuan University. Dec 13, 2018. Chengdu, China.

74. Extracellular Vesicle for Regeneration Medicine. Mayo Clinic. Nov. 29-Dec.1, 2018. Scottsdale, AZ.

75. Nanoplasmonic Quantification of Tunor-derived Exosome, Baylor Scott & White Research Institute. Nov. 2, 2018. Dallas, TX.

76. Small platform enables big change – Nanotech-assisted discovery of novel biomarkers for disease diagnosis. 2018 ACS annual meeting. August 18-23, 2018. Boston, MA.

77. Sentinels in the blood: nanotech-enabled biomarker discovery for disease diagnosis. University of California San Diego, July 19, 2018. San Diego, CA.

78. Nanotech-enabled Discovery of Novel Bio-signatures in Blood. Jilin University, July 5, 2018. Changchun, China.

79. Quantification of Circulating Mtb Antigens via Nanopore Technologies. 13^th Sino-US Nano Symposium, June 22, 2018, Chengdu, China.

80. Nanotech-enabled Discovery of Novel Bio-signatures in Blood. National Center of Nanotechnology and Nanosceince, June 25, 2018. Beijing, China.

81. Personalized diagnosis of M. tuberculosis in Children. Pediatric World Summit. June 22. Madrid, Spain.

82. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. CIMTEC 2018. June 14, 2018. Perugia, Italy.

83. Blood trial – Liquid Biopsy Nanomedicine. National Institute of Infectious Diseases in Italy. June 5, 2018. Rome, Italy.

84. Absolute Quantification of Mtb Antigens in Blood. China CDC Annual Meeting. May 24, 2018. Jishou, China.

85. Quantification of Circulating Exosomes for Early Detection of Cancer. Great Wall Clinical Lab Medicine Conference. May 18, 2018. Beijing, China.

86. Rapid Quantification of Circulating Extracellular Vesicles for Cancer Screening. University of California Los Angeles. March 14, 2018. Los Angeles, CA.

87. Spinning Biological Trash into Diagnostic Gold. Mayo Clinic. March 9, 2018. Rochester, MN.

88. Nanotechnology-assisted Biomarker Discovery and Evolution. Weill Cornell Medicine, January 10, 2018. New York City, NY.

89. Small Platform enables Big Changes. Pennsylvania State University Medical School, January 8, 2018. Hershey, PA.

90. Written in Blood. University of California San Diego, December 15, 2017. San Diego, CA.

91. Nanotechnology-assisted Biomarker Discovery and Evolution. Clinical Diagnostics & Research Virtual Conference, November 8-9, 2017.

92. Nanodisk-MS for Diagnosing Mycobacterial Infection. China Anti-TB Association Annual Conference, November 3, 2017, Shaoxing, China.

93. Quantification of Circulating Pathogen-derived Exsomes for Personalized Diagnosis. Soochow Univesity, November 1, 2017, Suzhou, China.

94. Walk in the Blood. Jiangnan University, October 31, 2017, Wuxi, China.

95. Nanotechnology enables the discovery of next generation biomarkers. National NSF Nanomedicine Seminar Series, October 13, 2017, Phoenix, AZ.

96. Pathfinder in Exosome Studies – September 22, 2017, Tsinghua University, China.

97. Nanotechnology-assisted Peptidomics Analysis for Diagnosing Mycobacterial Infection. September 20, 2017, The Institute of Biophysics, Chinese Academy of Science, China.

98. Nanoplasmonic Quantification of Tumor-Derived Extracellular Vesicles in Plasma Microsamples. 254^th American Chemical Society National Meeting. August 20-23, 2017. Washington DC.

99. Written in Blood - Nanotech-enabled Discovery and Quantification of Blood Biomarkers. August 16, 2017, George Washington University, Washington DC.

100.Nanoplasmonic Quantification of Tumor-Derived Extracellular Vesicles in Plasma Microsamples. Next Generation Dx Summit 2017. August 15-18, Washington DC.

101.Quantification of Circulating Antigen Peptidomes for Rapid Diagnosis of Mycobacterium Infection. August 3, 2017, University of California San Diego, CA.

102.Leveraging the Power of MALDI-TOF MS. American Association of Clinical Chemistry 2017 Annual Meeting. August 1-3, 2017, San Diego, CA.

103.Nanotech-enabled Biomarker Discovery and Quantification. Southern Technological University. July 2017, Shenzhen, China.

104.Nanoplasmonic Quantification of Tumor-Derived Extracellular Vesicles for Pancreatic Cancer Early Detection. June 1, 2017, Mayo Clinic, Rochester, MN.

105.Nanotechnology Assisted Rapid Blood Circulation for Tuberculosis Antigen Detection. The 2017

National Conference of the China Medical Association TB Society (CMA-TB). May 2017. Xiamen, China.

106.Novel Serum-based Biomarkers for the Diagnosis and Monitoring of TB Treatment Response in Children. The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network Annual Meeting 2017. May 2017. Washington D.C.

107.Absolute Quantification of Circulating Mtb antigents for Rapid Diagnosis. The 11th Shanghai Conference on Tuberculosis. March 2017. Shanghai, China.

108.Nanotech-enabled Discovery and Quantification of Blood Biomarkers. St. Paul Hospital & The University of British Columbia. January 2017. Vancouver, Canada.

109.When Less is More. Mayo Clinic. January 2017. Scottsdale, AZ.

110.Nanoplasmonic quantification of tumor-derived exosome. ACS Southwest Regional Meeting (SWRM) 2016. November 2016. Galveston, TX.

111.Spinning the Biological Trash into the Diagnostic Gold. Chemistry Department at University of California Los Angeles. October 2016. Los Angeles, CA.

112.Exosomal EphA2 Transmits Chemoresistance and Predicts Pancreatic Cancer Patient Responses to Therapy. HUPO world congress 2016. September 2016. Taipei, Taiwan.

113.Rapid Quantification of Circulating Peptides for Tuberculosis Detection. American Society for Microbiology Annual Meeting 2016. May 2016. Boston, MD.

114.Application of Nanoengineered Materials in Translational Molecular Diagnosis. Arizona State University. March 2016. Tempe, AZ.

115.Nanopore-enabled peptidomic analysis for disease detection. The University of Texas M.D. Anderson Cancer Center. November 2015. Houston, TX.

116.Written in Blood – Circulating Peptidomic Pattern for Cancer Detection. Georgia State University. August 2015. Atlanta, GA.

117.Absolute Quantification of Circulating M. Tuberculosis Antigens for Rapid Diagnosis and Real-time Treatment (Plenary Speech). The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network Annual Meeting 2015. June 2015. Washington D.C

118.“Small” Platforms Enabling “Big” Changes in Disease Detection. March 21, 2015. Houston Global Health Conference 2015. March 23, 2015. Rice University, Houston, TX

119.Nanopore-enabled circulating peptidomic analysis for the prevention of chemotherapy-induced cardiotoxicity. March 20, 2015. National Heart Lung Blood Institute. Bethesda, MD.

120.Nanodisk-MS platform for real-time identifying MDR-TB. December 5, 2014. National Institute of Allergy and Infectious Diseases. Bethesda, MD.

121.Nanopore-enabled Peptidomic Biomarker Discovery and Quantification for Cancer Diagnosis.

November 20, 2014. The University of Texas M.D. Anderson Cancer Center. Houston, TX.

122.NanoEngineering for Next Generation Biomarker Discovery, Oct. 27, SWOG annual meeting, Chicago.

123.Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer. Oct. 21, Baylor College of Medicine. Houston, TX

124.Nanopore-based Assay for Early Detection of Active tuberculosis, Sept. 19, 2014, Tongji University, Shanghai, China

125.Early Detection of Pancreatic Cancer with Circulating Peptidomic Signature, Sept. 13, 2014. The 8th Chinese Conference on Oncology, Jinan, China.

126.Nanopore-enabled analysis and its application in disease detection, Sept. 8, 2014. NIH Clinical Center, Bethesda, MD.

127.Serum Peptidomic Biomarkers Identified by means of a Nanopore-based Assay. July 15, 2014, John Hopkins Medical Institute. Baltimore, MD.

128.Peptidomic Analysis with Nanopore Technology. Mar. 10, 2014. Purdue University, West Lafayette, ID.

129.Nanopore-enabled biomarker detection on mass spectrometry for infectious disease, Feb. 2, 2014. The university of Texas at Tyler. Tyler, TX.

130.Mesoporous Material Enabled Diagnostic Platform for HIV/TB Co-infection. Jan. 15, 2014. Tianjin Tumor Hospital, Tianjin, China.

131.Nanopore Assay for Low Abundance Blood Biomarker Discovery and Quantification from Human Bodily Fluids. Sept. 5, 2013. Florida International University, Miami, FL.

132.Mesoporous material enabled diagnostic platform for HIV/TB co-infection. Aug. 10-14, International MRS, Cancun, Mexico, 2013.

133.Profiling the progress of breast cancer lung metastasis with low molecular weight peptidome. Apr. 6, 2013. Arizona State University. Tempe, AZ.

134.Surface Engineering of Mesoporous Silica Films and their Application in Selectively Harvesting Low Molecular Weight Protein. Jul. 15, 2012. Naples University, Italy.

135.Nanodevice in the Advanced Diagnosis. Jun. 8, 2012. Nanyang Technological University, Singapore.

136.Selective Enrichment of LMW Proteomics with Tunable Mesoporous Silica Substrates. Jun. 3, 2012. Tsinghua University, Beijing, China

137.The Next Generation of Proteomic Nanochips for Biomarker Discovery. Oct. 1, 2011. Weill Cornell Medical College of Cornell University, New York City, NY.